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Abstract: Though Cannabis sativa has been used as a medical treatment for centuries, 
recent American political controversy surrounding the legalization of marijuana has 
generated interest into the mechanism of cannabinoid biosynthesis.  This biosynthetic 
pathway involves enzymes derived from genes which produce the major cannabinoids of 
interest within C. sativa.  Δ9-Tetrahydrocannabinol (THC) has been predominant in 
investigations due to numerous reported beneficial effects for various symptoms such as 
those associated with cancer treatment.  Non-synonymous single nucleotide 
polymorphisms (SNPs) within the THCA synthase gene responsible for enzymatic 
production of THC change the nucleotide sequence and subsequent amino acid sequence 
for the enzyme.  These changes could potentially alter the efficacy of the enzyme that 
produces THC.  In the current investigation, permission was granted by Oklahoma State 
University to handle small samples of C. sativa within the School of Forensic Science 
student laboratories.  The Tulsa Police Department provided small samples of C. sativa 
seized previously and marked “to be destroyed”.  In these samples, four single nucleotide 
polymorphisms within the THCA synthase gene were analyzed via SNaPshot® analysis 
and amplicon sequencing.  The concentration of THC was determined using gas 
chromatography-mass spectrometry.  Correlation statistics were performed to determine 
if a correlation existed between the concentration of THC and the activity of the THCA 
synthase gene.  No correlation existed between THCA synthase SNP profiles and THC 
concentration.  If a correlation existed, genetic analysis of the C. sativa THCA synthase 
would provide growers, providers, distributors, and users of medical marijuana with more 
pertinent information about the quality of C. sativa products available. 
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 The controversy surrounding the legalization of marijuana has existed for many years and 
remains a polarizing topic in American society and especially politics.(1)  Prohibition of 
marijuana, or Cannabis sativa L (C. sativa), began with the passage of state legislation in the 
early 1900s.(2)  On a federal level, C. sativa is currently listed as a Schedule I controlled substance 
under the Comprehensive Drug Abuse Prevention and Control Act of 1970.(3)  Since its initial 
listing in 1970, C. sativa has become the most widely used illicit drug within the U.S.(1)  
Beginning in 1996, however, states have individually started decriminalizing the use of C. sativa 
for both medical and recreational purposes.  Currently, 23 states and the District of Columbia 
have enacted legislation that permits the medical use of C. sativa.(4)   
 Although states within the U.S. have started enabling the medical use of C. sativa, a 
variety of legal and other issues continue to present problems.  While some states permit the use 
of C. sativa for medical purposes, individuals receiving, prescribing, growing, and distributing 
the plant are still subject to punishment for violations of federal law and can therefore be charge 
with federal crimes.(1)  Other problems include more medically relevant dilemmas about C. 
sativa, including the variation of dosage level within the plant, variation of individuals’ unique 
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physiological response to the plant, and variation of types and levels of other chemical 
components within the plant.(1),(5) 
 C. sativa contains more than 60 chemical compounds, called cannabinoids.(6),(7)  Of these, 
Δ9- tetrahydrocannabinol (THC) is the main psychoactive ingredient.(1)  Another cannabinoid 
called cannabidiol (CBD), also present in C. sativa, may have various beneficial effects on 
individuals when used as a medical treatment for uncontrollable seizures.(8)  Studies have shown 
that these cannabinoids may be helpful in treating a variety of illnesses ranging from Crohn’s 
disease to fibromyalgia as well as ameliorating the pain and toxic effects of chemotherapy for a 
variety of patients suffering from malignant disease.(1),(9),(10)  However, the concentration of the 
cannabinoids within C. sativa prescribed to these individuals is often unknown.(1)   
 A variety of factors influence the chemical composition of C. sativa: the geographical 
origin of the plant, the part of the plant selected for use, the way in which the plant parts are 
stored, and the specific growth conditions used during propagation of the plant.(7)  Of the 
numerous techniques available to analyze the chemical composition of C. sativa,  the majority 
involve chromatography.  Chromatography separates chemical compounds based on mass or size, 
solubility, or attraction to chemical characteristics of a solid matrix.(11)  The primary methods 
used to determine the type and quantity of cannabinoids present in samples of C. sativa  are thin 
layer chromatography, high pressure liquid chromatography, and gas chromatography.  Mass 
spectrometry can be paired with gas or liquid chromatography to identify and quantify the 
amounts of cannabinoids in extracts.(12)  Often used in forensic investigations, these techniques 
provide information about the chemical composition of the sample in question.(11) 
 Other methods to assess the characteristics of C. sativa involve genetic analysis.  In fact, 
a partially completed genome sequence of the C. sativa plant has been published in Gen Bank, 
although numerous gaps remain in the sequence.(13)  The discovery of cannabinoids within C. 
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sativa sparked interest in the biological mechanism(s) used by the plant to synthesize these 
compounds biosynthetically.  A complete understanding of cannabinoid biosynthesis remains 
unclear and continues to be investigated.(14)  However, recent evidence suggests that THC and 
CBD are synthesized through the activity of two enzymes, THCA synthase and CBDA synthase 
respectively, from a precursor known as cannabigerolic acid (CBG) that is derived from a 
pathway involving olivetolic acid, one of the precursors of all cannabinoids.(15)  After enzymatic 
activity occurs, the cannabinoids Δ9-tetrahydrocannabinolic acid (THCA) and cannabidiolic acid 
(CBDA) spontaneously decarboxylate into their neutral forms THC and CBD, respectively.  
Because of high interest in THC, the main psychoactive compound, research has focused on the 
enzyme THCA synthase that converts CBG to Δ9-tetrahydrocannabinolic acid or THCA, which 
then spontaneously is decarboxylated (especially during heating) to THC.  The enzyme involved 
in the synthesis of THCA is expressed by the THCA synthase gene that has been identified and 
characterized by nucleotide sequencing.  The THCA synthase gene contains no introns and 
essentially represents the coding sequence for the enzyme.(16)  Several studies have identified 
specific single nucleotide polymorphisms (SNPs) within the THCA synthase gene that are 
claimed to correlate with the production of THC. (16),(14),(17)  Some studies claim to be able to 
distinguish “active” from “inactive” THCA synthase genes based upon the SNPs present in the 
gene and the chemical cannabinoid content of the mature plant. (16),(17) 
 Variations within the genes that code for synthesis of THCA have been analyzed.  These 
variations, or polymorphisms, occur at specific nucleotide positions within the gene.  One 
published study revealed that C. sativa can have up to 62 single-nucleotide polymorphisms in the 
THCA synthase gene.(16)  Furthermore, the study showed that these mutations in the THCA 
synthase gene can either create premature stop codons, or change up to 37 amino acids within the 
primary sequence.(16)  The changes in amino acid sequence in the THCA synthase gene can affect 
the activity of the THCA synthase enzyme.(17)  Rotherham and Harbison, for example, analyzed 
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four specific single-nucleotide polymorphisms (SNPs) in the THCA synthase gene.(17)  The 
authors claimed that these specific SNPs correlated with THCA synthase activity and THC 
content in the mature plant.  Thus, their results demonstrated that these SNPs determined the level 
of activity of THCA synthase within individual C. sativa plants, as revealed by the THC content 
at maturity.  Samples were found to genotype as homozygous for the active form of THCA 
synthase, heterozygous for both active and inactive forms, or homozygous for the inactive form 
of THCA synthase, and these genotypes correlated with the chemical content of THC in the 
plants.(17)   
 The study by Rotherham and Harbison created an opportunity for further investigation of 
the relationship between single-nucleotide polymorphisms and their effects on the activity of 
THCA synthase, and hence the levels of cannabinoids present in C. sativa.  In the case of their 
study, forensically seized samples were obtained in New Zealand.  Similarly, the research 
presented here assessed the genotype and chemotype relationship in C. sativa samples seized in 
the Tulsa area by the Tulsa Police Department.  Thus, the genotype/chemotype relationships in 
plants possibly originating from a different geographical location of the world could be 
investigated.  In addition, the work of Rotherham and Harbison focused upon SNPs existing 
within a 399 base-pair region of the 1635 base-pair THCA synthase gene, and was concerned 
with only four SNPs known to cause significant changes in the amino acid sequence of the 
synthase polypeptide.(17)  Thus, additional SNPs elsewhere within the gene could be examined.  
Lastly, the Rotherham and Harbison study distinguished what constituted “drug-type” and “fiber-
type” samples by analyzing the level of cannabinoids by gas chromatography-mass spectrometry 
(GCMS).  The specific quantities of cannabinoids in each sample were correlated to the results 
from genetic analysis.  The potential correlation between these two analyses could be useful for 




 The proposed research will investigate C. sativa for the reported correlation between the 
quantities of the various cannabinoids in the chemical composition of the mature plant and the 
genotype of the THCA synthase gene.  This correlation would enable the prediction of the final 
composition of cannabinoids in a mature plant based on the genetic analysis of seeds, pollen, or 
young plants before maturity which is the time cannabinoid biosynthesis is maximal.  This 
information would be useful for growers to be confident of the characteristics of the plant they 
will ultimately harvest for medical purposes.  To determine the chemotype (independent 
variable), I will use gas chromatography with mass spectrometry to analyze cannabinoids present 
in C. sativa plant material.(11) To determine the genotype of the same samples (dependent 
variable), I will perform genomic analysis of 4 specific single-nucleotide polymorphisms in the 
THCA synthase gene directly responsible for the synthesis of THCA; this enzyme is involved in 
producing one of the principal cannabinoids in C. sativa.(17) 
 The results of this study could confirm the correlation between genotype and chemotype 
of C. sativa, initially reported by Rotherham and Harbison.(17)  This confirmation could allow 
genotypic analysis of seeds or other plant material in a predictive manner concerning the 
cannabinoid content of mature plants.  This information would enable growers, medicinal 
providers, dispensaries, and users of medicinal marijuana to choose the quality of desired plant 
product based on the genetic blueprint for production of cannabinoids by C. sativa seeds.   
 The following chapter will review the available literature about C. sativa.  This review 
will include a discussion of the legislation of C. sativa, the medical uses of C. sativa, the 





 LITERATURE REVIEW  
 
 As discussed previously, controversial political debates increasingly focus on the use of 
medical and recreational marijuana.  C. sativa is also the most commonly used illicit drug in the 
world.(6),(15)  For thousands of years people have used Cannabis sativa L. (C. sativa), or 
marijuana, for a number of reasons including recreational and medicinal purposes. (8), (15), (18)  
However, because of its psychotropic effects, among other factors, C. sativa is currently listed as 
a federally controlled substance within the United States.(3)  People experience these 
pharmacologic effects because of the specific chemical compounds of C. sativa called 
cannabinoids.(8) The following review will discuss literature concerned with legislation of C. 
sativa, the previously demonstrated medicinal treatments using C. sativa, the primary 
cannabinoids found in strains of C. sativa, as well as the justification for further analysis of the 
cannabinoids within C. sativa. 
Legislation of Cannabis sativa 
 Previous Legislation 
 Regulation of C. sativa in the United States began in the early 1900s from a state 
legislation perspective.  Until this time, the use of C. sativa for medicinal purposes was legal.  
However, New York and Utah enacted legislation that restricted the use or sale of C. sativa. 
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Soon after, many other states also enacted legislation that restricted the sale or use of marijuana.  
The shift from state regulation to federal regulation occurred with the passage of two important 
Acts.(2)  The Uniform Narcotic Drug Act, enacted in 1932, prohibited anyone from 
“manufacturing, possessing, selling, purchasing, prescribing, administering, or giving away any 
narcotic drug.”(19)  The Marihuana Tax Act, enacted in 1937, required any manufacturer, 
distributor, prescriber, vendor, or individual who gives away marijuana to register and pay taxes 
in order to provide their service.(19)  These two Acts were the first to federally enforce the 
regulation and restriction of sale and use of C. sativa. 
 Years later, a prevalence of narcotic abusers motivated the public to call for reform.  
Thus in 1951, the United States Congress passed the Boggs Act, that listed marijuana as an illicit 
substance along with other narcotics for the first time.  The Boggs Act also called for more strict 
consequences for abusers and sellers of narcotics and C. sativa.  With the passage of the 
Narcotics Control Act of 1956, the penalties for the illegal activities increased again.  Specifically 
for abusers and sellers of C. sativa, the increase would enable more control from law enforcement 
on restriction of use, sale, and manufacturing of marijuana.  The Narcotics Control Act also 
increased the enforcement of narcotics regulation.(2),1 
 Recent Legislation 
 After nearly a century of state and federal legislation opposing the manufacture, 
possession, use, sale, and distribution of C. sativa, California became the first state to legalize its 
use for medical purposes in 1996.(20)  The decriminalization of C. sativa has since spread 
                                                           
1 When the Narcotics Drug Act of 1957 was passed, it enabled U.S. Customs and Narcotics Bureau agents to carry 
weapons, as well as arrest suspected violators without need of a warrant.  The government could appeal judicial cases 
in which evidence was suppressed.  It also provided witnesses with immunity in exchange for testimony.  A new 
category of laws was enacted regarding communication of drug sale, trade, and trafficking to enable use of wiretapping.  
Furthermore, individuals found guilty of drug offenses were required to register with U.S. immigration authorities upon 
entrance or leaving the U.S.  Illegal immigrants who were found guilty of drug offenses would also be deported under 




throughout the United States.  Currently, 23 states and the District of Columbia have legislation 
enabling the medical use of C. sativa.(4)  Regardless, C. sativa remains listed as a schedule I 
federally controlled substance.(3)  Therefore, although state legislature enables patients to use 
medicinal marijuana with authorization, federal law provides for enforcement of penalties for 
these individuals.(21)  
Medical Use of Cannabis sativa 
 C. sativa has been used as a medication for centuries.  Bostwick discusses previous uses 
of the plant; he states that a physician in the 1830s originally prescribed C. sativa for pain and 
vomiting, much like the medicinal uses today.(1)  More modern research about the medical 
benefits of C. sativa is extensive.  The best documentation about the use of the plant pertains to 
research involving C. sativa as a treatment for the side effects of chemotherapy.(8)  Much of the 
initial research on C. sativa in the 1990s studied the reversal of weight loss seen in cancer patients 
as well as AIDS patients because of its appetite promoting effects.(1),(22)  
 Diseases 
 Scientists and medical experts have found that numerous symptoms of diseases and 
ailments other than cancer can be benefitted when patients are treated with C. sativa.  In a 
comprehensive review, Gurley et al state that C. sativa alleviates symptoms such as nausea and 
vomiting, muscle spasms, loss of appetite, menstrual pain, pain associated with child birth, 
seizures, and anxiety.  The effects of treatment using C. sativa have been studied in illnesses such 
as cholera and rabies, glaucoma, pain syndromes, addiction syndromes, and withdrawal 
syndromes.(8)   
 Other studies target specific illnesses such as Crohn’s disease.  A study by Naftali et al 
investigated the potential benefits of the treatment of Crohn’s disease with C. sativa.(9)  In a study 
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of 30 patients, every single patient stated that using C. sativa improved their symptoms.  
Specifically, results showed treatment with C. sativa decreased the number of bowel movements, 
the number of necessary prescribed treatments (including steroids), and the number of necessary 
surgeries.  These results demonstrated a measurable significant improvement of the symptoms of 
Crohn’s disease in 21 of the 30 patients who were treated with C. sativa.(9) 
 Along with Crohn’s disease, medical use of C. sativa for other inflammatory bowel 
diseases has been investigated.  Allegretti et al surveyed patients with IBD to assess the effects of 
the treatment on their symptoms.(23)  In this study, the majority of patients described use of C. 
sativa as “very helpful” to or “completely relieving” of their abdominal pain, nausea, and loss of 
appetite.  However, the patients noted the least amount of improvement in their diarrheal 
symptoms.  Because most of the symptom showed improvement with the exception of diarrhea, 
results of the study show the physiological mechanism of C. sativa metabolism remains unclear.  
These results contribute to the fact that IBD has not been approved statewide for treatment with 
medicinal C. sativa.(23)  
 Another disease that is currently being researched for treatment with C. sativa, 
particularly for the effects on patients’ pain, is fibromyalgia.  One study performed assessments 
on 56 patients.(10)  The results show that the patients experienced “significant relief of pain, 
stiffness, relaxation, somnolence and perception of well-being” after treatment with C. sativa.  
Thus, all symptoms assessed in this study showed significant improvement after administration of 
C. sativa.(10) 
 Epilepsy and other seizure disorders are conditions for which approval has been obtained 
in some states for treatment with C. sativa.(8)  Studies by Welty et al and Szaflarski and Bebin 
have reviewed previous research involving the treatment of epilepsy with C. sativa and found that 
evidence supporting the claim is “scarce”,(24) “anecdotal, weak, and occasionally 
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contradictory”.(18)  However, numerous other ailments have been approved for treatment with 
C. sativa, including migraines, glaucoma, and arthritis.(4)  
 Complications 
 As much literature as is available about the beneficial effects of medical treatment using 
C. sativa for various illnesses, many articles describe the negative effects or drawbacks of 
C. sativa treatment.  Pertaining to the legalization standards, one study notes that, regarding 
C. sativa in medical use: 
“[P]roducts are not produced under the guidance of good manufacturing practices (GMP) 
and are not subject to regulations governing labeling, purity, and reliability.  In other 
words, there is no guarantee of consistency between products, or even differing lots 
produced by the same manufacturer.”(24)  
 Leung discussed other complications regarding treatment in another article.(5)  This study 
showed that 1 in 10 people who have used C. sativa develop dependence.  Leung also indicated 
that when people smoke C. sativa, levels of cannabinoid quantity vary with individual 
consumption based on unique physiology and technique of inhalation.  Furthermore, the 
cannabinoid content of C. sativa can also vary based on the geographic origin of the plant, the 
part of the plant being used, the way the plant is stored, or the way in which the plant is grown.  
Thus, standardization of a prescription is difficult due to the titration, or unknown concentration, 
and dose efficacy of C. sativa.(5) 
 Many studies show overwhelming evidence of withdrawal symptoms after patients cease 
treatment with C. sativa (1),(5),(8),(18),(25),(26)  The most common symptoms of withdrawal include 
sleep disturbance,(1),(18),(25),(26) changes in appetite,(18),(25),(26) irritability,(1),(25),(26) anxiety,(1),(26) 
weight loss,(1),(25) restlessness,(1),(25) cravings,(1),(18) and aggression.(18),(25)  Szaflarski and Bebin 
report other symptoms of withdrawal from C. sativa treatment such as insomnia, delirium, 
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moodiness, somnolence, fatigue, and diarrhea.(18)  Ramesh et al also note withdrawal symptoms 
of anger and sweat or chills.(25)  Depression has also been investigated as a withdrawal effect from 
C. sativa treatment.(26)  
 The connection between the consumption of C. sativa and psychosis has also been 
studied.(1),(6),(8)  In a comprehensive review, Gurley et al indicate that no direct evidence exists 
concerning psychosis presumably caused by the use of C. sativa.(8)  However, the study notes that 
the use of C. sativa can worsen the pre-existing symptoms of patients who already have psychotic 
illness.  In another review, Bostwick showed a correlation between use of C. sativa and psychotic 
illness; however, he states “the question of whether cannabis causes psychosis remains 
unresolved.”(1)  The review assessed many studies involving C. sativa treatment for psychotic 
illnesses such as schizophrenia.  Similar to the study by Gurley et al, Bostwick demonstrated that 
use of C. sativa exacerbates the symptoms of illness within individuals with psychotic 
disorders.(1),(8) 
Cannabinoids of Cannabis sativa 
 The psychotropic effects of THC present in C. sativa are the primary reasons for the legal 
restrictions of C. sativa use.(3)  Within various strains of C. sativa are compounds that influence 
these psychotropic effects.  These compounds are collectively called cannabinoids.  C. sativa 
contains over 400 chemical compounds, of which more than 60 are cannabinoids.(6).(7)   
 Biosynthesis of Cannabinoids 
 As discussed previously, recent interest in the medical/recreational use of marijuana has 
sparked investigations of the biosynthetic pathway(s) used by the plant to produce cannabinoids.  
The primary cannabinoids, cannabidiol, or CBD, and Δ9-tetrahydrocannabinol, or THC, are 
products from the non-enzymatic decarboxylation of the actual end products of biosynthesis: 
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CBDA and THCA.  These acids are formed from a primary compound, olivetolic acid, that is 
converted to cannabigerolic acid or CBGA, which then is converted to either CBDA or THCA 
from the action of THCA or CBDA synthase, the enzymes that functionally produce CBDA and 
THCA, respectively.  The figure below shows the principal steps in the biosynthetic pathway. 
 
 Figure 1: Cannabinoid Biosynthetic Pathway  
 











The biosynthetic pathway above depicts how olivetolic acid forms cannabigerolic 
acid, which then breaks into THCA or CBDA through the action of THCA synthase 
and CBDA synthase, respectively.  The two cannabinoids THCA and CBDA 











Shown here is an example of a mature female Cannabis sativa plant.  The dried inflorescences 
analyzed in the current study are the light green, bushy material grown above the leaves.  
These inflorescence, or buds, are the flowering part of the plant, and are the primary site of 
cannabinoid biosynthesis within C. sativa. 
 Biosynthesis of cannabinoids is maximal in the glandular trichomes of the flowering 
buds, or inflorescence of the mature female C. sativa plant (Figure 2).(15)   
 





 One report by the United Nations describes the concentration of cannabinoids in other 
parts of the plant; the report demonstrates that leaves next to the inflorescence may also contain 
high levels of THC, but the concentrations are lower than that of the flowering buds.  Also noted 
are the minimal levels of THC in stems and the lack of any significant THC in seeds.(12)  Along 
with variation of cannabinoid concentration based on parts of the plant, concentration of 
cannabinoids within C. sativa plants varies based on geographical origin.(5),(7),(12)  These variations 
within cannabinoid concentration may influence the marijuana user’s selection of plant.(12) 
 Cannabidiol 
 Present in high quantities in some strains, cannabidiol (CBD) is one of the main 
cannabinoids of C. sativa.(7),(27),(28),(29)  Some studies show that CBD concentrations can reach as 
high as 40% of the dry weight of mature plants in some strains.  Although CBD does not affect 
individuals in a psychoactive manner, research demonstrates that the cannabinoid can be used to 
treat other conditions.(7)  Rajesh et al discuss the beneficial effects of CBD.(7)  The study indicates 
that CBD may serve as an antioxidant or anti-inflammatory agent and also showed 
immunomodulatory effects.  Results from this study demonstrate that CBD may serve to treat 
diabetes mellitus along with treating pain, inflammation disorders, and multiple sclerosis. 
 Another study by Gomes et al discussed the antipsychotic properties of treatment using 
C. sativa containing high concentrations of CBD.(29)  The study showed that CBD may have 
potential to treat the cataleptic symptoms of Parkinson’s disease, but the contradictory results 
warrant further investigation.  Along with Parkinson’s disease and other striatal disorders, the 
antipsychotic effects of CBD were reviewed by Zuardi and coauthors (2006).  Similar to the study 
by Gomes et al, the review by Zuardi et al reveals that CBD reduced catalepsy, or muscular 
rigidity, showing that CBD has potential for use as an antipsychotic treatment.(29),(30)  
Additionally, the study reviewed the possible use of CBD as a treatment for schizophrenia and 
found that CBD effectively treats psychotic symptoms in 2-4 weeks.  Using CBD, patients 
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experience equivalent improvement to other antipsychotic treatments.  However, unlike other 
treatments, CBD produced no side effects when treating psychotic illness.(30)   
 Δ9-Tetrahydrocannabinol 
 Contrary to the non-psychotropic effects produced by CBD, Δ9-tetrahydrocannabinol 
(THC) is attributed as the main psychoactive cannabinoid in C. sativa.(24),(25),(26) Research has 
shown that the two cannabinoids (CBD and THC) have adverse or opposing actions and 
effects(6),(27)  Furthermore, CBD has been demonstrated to decrease, block, and prevent the effects 
of THC.(6)  In the study by Gomes described above, the author states that CBD attenuates or 
reduces the effects of THC.(29)  THC and CBD are also described as isomers,(31) which are 
compounds that contain the same atomic elements but differ in structure.(32)  These two 
cannabinoids, therefore, share many similarities while producing quite different effects on 
individuals. 
   Although THC and CBD are the most abundant cannabinoids,(31) the proportions of 
these two compounds often vary within strains of C. sativa.  In fact, the THC to CBD ratio is 
described as the definitive characteristic of Cannabis variation.(27),(33),(34)  Often defined by 
percentage of THC content, the strains of C. sativa used for current medical purposes typically 
have higher percentages of THC than other cannabinoids.(33)  Tambaro and Bortolato also note 
that strains of cannabis distributed in the illegal arena typically present higher concentrations of 
THC and such strains typically have a much reduced content of CBD.(34)  Thus, there seems to be 
an inverse relationship between the levels of THC and CBD in a given strain, perhaps reflecting 
the competition between THCA synthase and CBDA synthase for the CBG precursor.    
 Potency of C. sativa is generally expressed in the quantity of THC present in the plant.(8) 
Since the psychotropic effects produced by THC are one reason the plant is federally controlled,(3) 
much research has been performed on the pharmacological effects of the cannabinoid.  
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Specifically, studies have investigated the agonistic actions of THC on the cannabinoid receptors 
CB1 and CB2.(7),(26) Additionally, one study by Holland et al investigated the toxicological 
characteristics of THC.  The study stated that cases of overdose from THC have rarely been 
reported.  Furthermore, in reference to the effects of THC within the body, the study 
demonstrated that “the detection window of cannabis impairment is poorly defined.”(35)  The 
primary research on cannabinoid action focuses on THC; the pharmacological actions of other 
cannabinoids are poorly understood and warrant further investigation. 
Analysis of Cannabis sativa 
 Chemotype  
 The content or chemical composition of cannabinoids in C. sativa, known as the 
chemotype, can vary significantly in different strains of C. sativa plants.  Factors such as 
geographic origin of the plant, as discussed previously, and cultivation methods can alter the 
cannabinoid content.  The study of cannabinoid biosynthesis can involve both the chemical and 
genetic analysis of plants.  Research has demonstrated that both techniques have been useful for 
understanding the nature of cannabinoid biosynthesis within C. sativa. 
 Chemotyping typically focuses on the separation of the cannabinoids using 
chromatography.  These techniques allow the compounds to be separated based on the chemical 
structure.  The most notably used chromatographic techniques for cannabinoids are thin-layer 
chromatography,(11),(12),(36),(37),(38) gas chromatography,(11),(12),(36),(37),(38) and high performance liquid 
chromatography.(11),(12),(36),(37)  Gas chromatography and liquid chromatography are often paired 
with mass spectrometry in order to further resolve and quantify the compounds.(34)   
 Thin-layer chromatography uses a stationary phase along with solvents to separate the 
cannabinoids of C. sativa extracts.(12)  The types of solid and liquid phases used vary based on the 
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polarity of compounds of interest.(36)  Some studies have used silica plates as the stationary phase 
when chemically analyzing extracts of C. sativa.(12),(36),(37),(38)  An extended report by the United 
Nations Office on Drugs and Crime (UNODC) explains suitable techniques that have been 
validated for analysis of C. sativa.  The report specifies the parameters for preparing thin-layer 
chromatography; the UNODC states that cannabinoids such as THC and CDB are easily soluble 
in many organic solvents.  Thus, a variety of methods are available for separation of cannabinoids 
via thin layer chromatography.(12)  The principal limitation of thin layer chromatography, 
however, is that the technique lacks sensitivity and may require multiple systems to separate 
complex mixtures.  Another issue of thin-layer chromatography results from the ambiguous 
separation and subsequent identification of cannabinoids from lack of adequate performance 
dependent on choice of method.(36)  
 In comparison to thin-layer chromatography, gas chromatography is more frequently 
used for the separation of cannabinoids in C. sativa.  Using this technique, C. sativa extract is 
heated until vaporized (which converts THCA and CBDA into their neutral THC and CBD 
counterparts), and carried by a gas through a thin column containing the stationary phase in order 
to separate the compounds.(11)  THC exists in plant material as a mixture of THC and THCA 
(tetrahydrocannabinolic acid).  THCA spontaneously decarboxylates into THC in the presence of 
heat;(33) thus, the heat associated with gas chromatography automatically converts any THCA into 
THC and allows for the complete determination of THC content.(12) A study by Hazekamp et al, 
that investigated various chromatographic techniques for the chemical analysis of C. sativa 
showed that many cannabinoids are easily fragmented when analyzed with gas chromatography 
coupled with mass spectrometry (GC/MS).(36)  Therefore GC-MS is a valuable technique for the 




 Genotype  
 Although chromatography allows for the separation and identification of cannabinoids 
through chemical analysis, molecular analysis of the cannabinoid synthase genes can also predict 
cannabinoid content according to literature.(17)  Some of the preliminary genetic studies on C. 
sativa utilized the molecular analysis for identification or tracing purposes.  For example, Linacre 
and Thorpe used the universal chloroplast transfer RNA gene sequences for the identification of 
C. sativa plants from different geographic origins.(39)   
 Knowledge of the biosynthetic pathway for cannabinoids, THC in particular, has caused 
considerable interest in the molecular biology of the THCA synthase gene.(16),(33),(40),(41),(42)   In a 
study by Marks et al (2009), RNA extracted from the glandular trichomes of C. sativa was used 
to construct a cDNA library that was then used to quantify the THCA synthase content in 
different tissues of the C. sativa plant.(33)  Results of the study showed that maximal expression of 
THCA synthase occurs in the trichomes.  Another study by Sirikantaramas et al cloned the THCA 
synthase gene to predict the characteristics of the THCA synthase protein and found that the gene 
encodes a polypeptide consisting of over 500 amino acid residues.(42)  Kojoma et al extended the 
results from Sirikantaramas et al and discovered polymorphisms within the THCA synthase gene, 
some of which would result in the production of non-functional THCA synthase enzyme due to 
the introduction of either a premature stop codon or alterations in the amino acid sequence.(16),(42)  
Over 60 nucleotide substitutions were identified in the THCA synthase gene by Kojoma et al that 
resulted in 37 amino acid substitutions within the synthase polypeptide chain.(16)   
 Rotherham and Harbison also used the reported sequence of the THCA synthase gene to 
develop a molecular assay designed to reliably analyze four specific single-nucleotide 
polymorphisms (SNPs) of the THCA synthase gene of C. sativa that changed the amino acid 
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sequence of the protein in a way that was predicted to inactivate the enzyme.  The results from 
this study showed that these four polymorphisms differentiate between the active and inactive 
form of THCA synthase.  The primers designed by Rotherham and Harbison for the molecular 
analysis of the four specific SNPs allowed for minisequencing of the specific SNP sites using a 
process generally known as SNaPshot® analysis.  The conclusion from the study of Rotherham 
and Harbison was that their assay of nucleotides present at the four SNP positions could reliably 
distinguish between active (drug-type) and inactive (fiber-type) THCA synthase genes in a plant 
and therefore predict the THC content of a mature C. sativa plant.(17) 
Summary 
 Research of C. sativa has provided the medical community with a foundation for the 
controversial debates about treatment using medical marijuana.(24)  Though  medical use of C. 
sativa has been prevalent throughout history, (8), (16), (18) the plant remains listed as a federally-
controlled substance within the United States.(3)  Legislation within certain states, however, has 
enabled individuals to treat symptoms of illnesses such as AIDS or glaucoma with C. sativa.(4)  
The psychotropic effects produced by THC are among the factors that limit the use of C. sativa 
under federal regulation.(3)  Research into the biosynthetic pathway of THC and other 
cannabinoids such as CBD continues to provide insight into the specific effects of C. 
sativa.(6),(15),(33),(31),(40),(41)  Many of the details about the chemical composition and biosynthesis 
remain unclear.(14)  Therefore, these gaps in research warrant further investigation of the 
chemotype and genotype of C. sativa.(17)  The methods proposed in this thesis will analyze some 








 Analytical techniques for assessment of cannabinoid content of Cannabis sativa include 
both genomic analysis and gas chromatography coupled with mass spectrometry (GC-MS).  
Genomic analysis includes DNA extraction, agarose gel electrophoresis, single nucleotide 
sequencing (i.e., SNaPshot® analysis),(17) capillary electrophoresis, and genomic sequencing.  
Genomic analysis using the method of Rotherham and Harbison allows for the detection of active 
and inactive THCA synthase genes of C. sativa according to the conclusions of their study. (17)  
Recall that this gene is directly responsible for the synthesis of the enzyme that converts CBG to 
THCA in mature C. sativa plants.  Gas chromatography coupled with mass spectrometry was 
chosen to detect and quantify cannabinoid content.(12)  
Selection of Cannabis sativa Samples 
 In order to analyze C. sativa samples in the School of Forensic Science laboratory at 
Oklahoma State University-Center for Health Sciences, permission was sought from the OSU-
CHS administration to work with small amounts of marijuana within the forensic student 
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laboratories.  After this permission was granted, a request was sent to the Tulsa Police 
Department (TPD) to provide small amounts of seized C. sativa evidence from former casework 
that was marked “to be destroyed.”  The TPD Evidence Custodian and the TPD Crime Laboratory 
Director obtained permission to support our project from the command staff within TPD. 
 After permission was granted to work with former evidence from the TPD, samples were 
selected from the property room.  Because storage of C. sativa may alter the cannabinoid content, 
samples were selected from case numbers created within the last two years.  Separate case 
numbers were also selected in an attempt to avoid repeat analysis of the same plant material in the 
different sample selection events (three in total over the course of the present study).  In addition, 
care was taken to select seized samples composed of individual inflorescences, or buds, to help 
ensure the likelihood that plant material was unique to an individual plant and also to maximize 
the THC chemical content of the material subjected to GC/MS.   
 Because C. sativa is a Schedule I federally-controlled substance,(3) precautions were 
taken for access and storage of samples.  During analysis, samples were accounted for at all 
times.  When samples were not needed in the laboratory for analysis, they were stored in a safe in 
an evidence room with controlled access.  Only the Chair of the School of Forensic Science and 
the Director of Quality have access to the safe.  A chain of custody log was also kept for the 
samples to show proof when the samples were handled, by whom, and the quantity of sample that 
was removed. 
Genetic Analysis 
 DNA Extraction 
 Extraction of DNA was performed using  an organic extraction protocol employing 
digestion of plant material in TNE buffer (10 mM Tris-Cl, pH 8.0, 0.15M NaCl and 0.1 mM 
EDTA; Thermo-Fischer, Waltham, MA) containing proteinase K (40 µg/mL; Promega Corp, 
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Madison, WI) and  sodium dodecyl sulfate (0.5% final concentration; Affymetrix, Santa Clara, 
CA) with incubation for 2 hours at 65°C.  Digested samples were then subjected to organic 
solvent extraction with a mixture (9:0.96:0.04 v/v/v) of phenol (MP Biomedicals, Santa Ana, CA) 
and chloroform:isoamyl alcohol (Sigma Aldrich, St. Louis, MO).  Before initial extraction, an 
extraction buffer was prepared that contained 25 µL SDS, 20 µL Proteinase K, and 955 µL TNE 
buffer.  Samples of 10-15 mg of plant material were weighed out and placed in labeled 0.6 mL 
microfuge tubes.  A spatula of glass beads was added to the tubes as well, in order to assist in 
breakage of plant material during mixing on the vortex mixer.  Then 250 µL of extraction buffer 
was added to each tube and incubated at 65 °C for 2 hours. 
 After incubation, for each sample, a hole was pierced into the bottom of the 0.6 mL 
microfuge tube before it was placed into a labeled 1.8 mL microfuge tube.  The liquid was 
centrifuged away from the residual plant material during a 1 minute centrifugation at 6000 x g.  A 
mixture of phenol:chloroform:isoamyl alcohol (9:0.96:0.04 v/v/v) solution was prepared and an 
equal volume of organic solvent was added to each extract in the 1.8 mL microfuge tube.  The 
samples were vortexed and placed in a centrifuge at 10,000 x g for 3 minutes.  The upper aqueous 
phase from each sample was recovered with a micropipette and placed into a labeled clean 1.8 
mL microfuge tube.  An equal amount (~250 µL) of chloroform:isoamyl alcohol (24:1) was 
added to each tube and the samples were vortexed again and centrifuged at 10,000 x g for 3 
minutes.  Again, the upper aqueous phase for each sample was collected using a micropipette and 
placed into a clean, labeled 1.8 mL microcentrifuge tube.  DNA was recovered from extracts 
using Zymo Clean and Concentrator-25 technology (Zymo Research, Irvine, CA) per 
manufacturer instructions, with the exception of a modification to the elution step.  After 
washing, samples were eluted two times in succession using 15 µL aliquots of TE-4 (10mM Tris, 
0.1mM EDTA) at 65°C.  The extracts were then ready for processing using polymerase chain 
reaction.  
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 Primer Selection and Optimization 
 Two different rounds of PCR required a variety of primer pairs for the SNaPshot® 
reaction.  The first pair, called C2E2, directs the amplification of a 400 base-pair segment of 
THCA synthase gene that harbors the four single nucleotide polymorphisms (SNPs) reported by 
Rotherham and Harbison.(17)  These SNPs were determined by Rotherham and Harbison to 
correlate with an active/inactive status of the THCA synthase gene.  The C2E2 primers were 
reconstituted in TE-4 to 100 µM stock solution, and aliquots of 10X primer pairs were made by 
performing a 1:10 dilution with TE-4.  The numbered pairs of primers were selected based on the 
SNaPshot® parameters used by Rotherham and Harbison, with the exception that three thymine 
nucleotides were added to the 5’ end of the 8F primer as shown below to obtain better separation 
of SNaPshot® products during capillary electrophoresis.  The concentrations of the SNaPshot® 
primers were as described in the Rotherham and Harbison study.(17)   The THCa and THCb 
primers were used to sequence the entire THCA synthase gene via Ion Torrent PGM. 
 
 








C2 F CAAACTKGTTGYTGTCCCATC 21 81°C 
E2 R CGTCTTCTTCCCAGCTGATC 21 82°C 
8F(*) TTTGAGTTGGGTATTAAAAAAACTGATTGCAAAGAATT 38 92°C 
9F CAACCATCTTCTACAGTGGTGTTGTAAATT 30 86°C 
16R TCRACTAGACTATCCACTCCACCA 24 82°C 
17R TACTGTAGTCTTATTCTTCCCATGATTATCTGTAATATTC 40 87°C 
THCa TGAAGAAAAAAAATGAATTGCTCAGCATTTTTC 33 69°C 
THCb TCTATTTAAAGATAATTAATGATGATGCGGTGG 33 66°C 
(*) The underlined nucleotides were added to the sequence published by Rotherham and Harbison.(17) 
 
24 
 Polymerase Chain Reaction 
 Polymerase Chain Reaction (PCR) was performed using GoTaq Hot Start® DNA 
polymerase (Promega Corp, Madison, WI) per manufacturer instructions.  The thermal cycling 
parameters used were those described by Rotherham and Harbison.(17) 
 To perform minisequencing, a 400 base-pair (bp) sequence of the THCA synthase gene 
was first amplified by PCR.  The C2E2 primer (Table 1) directed the amplification of the 400 bp 
amplicon using approximately 1 ng of genomic DNA template.  Following amplification, the 
400 bp amplicon was visualized via agarose gel electrophoresis both to confirm that product had 
been amplified and also to get a rough estimate of product concentration.  A 1.5% gel was made 
by adding 1.125 g agarose (Invitrogen, Waltham, MA) to 75 mL 1X TAE (Tris-Acetate-EDTA, 
pH 8.0) buffer (Invitrogen; Waltham, MA) and heating the mixture to solution in a microwave for 
approximately 90 seconds.  Following partial cooling of the gel solution, 15 µL of 10 mg/mL 
ethidium bromide (MP Biomedicals, Solon, OH) was added to the molten agarose which was then 
poured into a gel mold and cooled to room temperature.  Then, 5 µL aliquots of PCR products 
were added to 10 µL of 1X TAE containing tracking dyes (bromophenol blue, Sigma-Aldrich, St. 
Louis, MO; xylene cyanol, BioRad, Berkeley, CA; and Ficoll, Sigma-Aldrich, St. Louis, MO ).  
Samples were loaded onto the gel along with two 100 bp size ladders (Invitrogen, Waltham, MA).  
The gels were electrophoresed at 70 volts for approximately two hours and then placed in a UV 
illuminator to confirm the presence of the 400 bp template for minisequencing. 
 Single Nucleotide Polymorphism Analysis 
 In order to analyze the four single nucleotide polymorphisms, the SNaPshot® 
minisequencing kit was used (Thermo Fisher, Waltham, MA).  SNaPshot® technology enables the 
nucleotide base at a predetermined position within the DNA molecule to be identified in a 
minisequencing approach.  For this research, primers for the SNaPshot® reaction revealed the 
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nucleotide at each of the four positions that Rotherham and Harbison suggested allowing active 
and inactive THCA synthase genes to be distinguished.(17)   
 SNaPshot® reactions were performed following the manufacturer’s protocol.  Briefly, the 
400 bp minisequencing template was subjected to removal of PCR primers and deoxynucleotide 
triphosphates (dNTPs) following a 1 hour incubation with a mixture of exonuclease and alkaline 
phosphatase (EXO/SAP, Affymetrix, Cleveland, OH).  The dilution of SNaPshot® products was 
also modified from a 1:10 dilution described by Rotherham and Harbison to between 1:50 and 
1:100 dilution in sterile deionized water which improved the overall quality of SNaPshot® results.  
All other SNaPshot® reaction steps were performed according to methods described by 
Rotherham and Harbison.(17)  Similar to PCR, SNaPshot® minisequencing uses DNA polymerase 
and primers to amplify template DNA.  However, SNaPshot® extends primers by a single 
nucleotide through the use of dideoxynucleotide triphosphates (ddNTPs).  Minisequencing 
primers were those described by Rotherham and Harbison with the exception of the addition of 
three thymine nucleotides to the 5’ end of the 8F primer, as discussed previously.(17)  This 
allowed for better separation between the minisequencing products containing the 8F and 9F 
nucleotide polymorphisms.  Visualization of SNaPshot® products was performed on ABI 3130 
capillary electrophoresis instrument using Gene Scan™ 120LIZ™ (Applied Biosystems, Waltham, 
MA) size standard and GeneMapper® (Applied Biosystems, Waltham, MA) analysis software 
(version 3.2), which allowed for visualization of electropherograms of capillary electrophoresis 
results.   
 Optimization of SNaPshot® 
 Methodology of SNaPshot® reactions were initially followed according to Rotherham and 
Harbison.(17)  The SNaPshot® settings were established in GeneMapper® (Applied Biosystems, 
Waltham, MA) analysis software (version 3.2).  After these settings were adjusted for optimal 
detection of the specific SNPs, the initial analysis of samples showed an abundant amount of off-
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scale results.  This effect happens when too much PCR product is loaded into the capillary 
96-well plate.  In order to counteract the occurrence of off-scale results, the dilution step within 
the SNaPshot® reaction described by Rotherham and Harbison was increased as discussed 
previously.17   
 Further optimization included determination of minimum relative fluorescence unit 
(RFU) in the allele peak heights for the SNPs.  Two samples were selected that were previously 
determined to be homozygous active and homozygous inactive, respectively.  These samples 
were processed with SNaPshot® five times to determine the minimum RFU setting appropriate 
for detection of SNPs.  By visualizing the areas of fluorescence baseline between peaks in the 
electropherogram, the level of baseline “noise” could be determined by setting the detection of 
RFU for each fluorescent dye at 1 RFU.  Any values below 1 RFU were determined to be 0.  The 
baseline noise showed values above 0 RFU where peaks for SNP positions were absent (Table 2). 
 
 
   Table 2: SNaPshot® Baseline Threshold Optimization 
Sample 8A 8I 9A 9I 16A 16I 17A 17I 
         
6043-1 62  84  49  63  
6043-2 39  52  39  40  
6043-3 46  56  42  47  
6043-4 71  89  62  73  
6043-5 35  44  29  73  
6922-1  14  31  36  43 
6922-2  0  13  28  20 
6922-3  0  18  20  24 
6922-4  0  17  21  0 
6922-5  0  17  16  15 
         The inactive sample 6043 and the active sample 6922 were selected for their THCA 
synthase activity determined from SNaPshot® results.  These samples were processed 
with SNaPshot® five times to determine the baseline threshold for the predetermined 
single nucleotide polymorphism positions within the THCA synthase gene.  Shown are 
the relative fluorescent units (RFU) for the absent active peaks of 6043 and the absent 
inactive peaks of 6922. 
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 These values were averaged for each absent peak across all SNPs and the standard 
deviation from these values was calculated.  Three times the standard deviation was added to the 
average to determine the minimum RFU detection threshold.  The values of each calculation are 
as follows. 
 
 Since 53 was the calculated minimum baseline RFU, the threshold RFU was set at 50.  
Results for the SNaPshot® reactions showed that samples either depicted homozygous-active, 
heterozygous, or homozygous-inactive SNPs for each position.  For example, if a homozygous-
active sample lacked an inactive peak at the 8F SNP position, all other SNP positions also lacked 
the inactive peak.  The RFU of each peak was typed into an Excel spreadsheet for statistical 
analysis.  Within the spreadsheet, ratios of active/inactive peak height RFUs were recorded for 
each SNP position.  These ratios were averaged within each SNP position for all samples, as well 
as within all SNPs for each respective sample (Appendix A). 
 THCA Synthase Amplicon Sequencing 
 Once the SNaPshot® reactions were performed, a select number of samples were chosen 
for partial gene sequencing analysis based on THCA synthase activity level demonstrated via 
SNaPshot® results.  Using the primers which direct the 400 bp amplicon discussed above, the 
seven selected samples were sequenced by staff in the Oklahoma State University School of 
 
   Table 3: SNaPshot® Baseline Threshold Calculations 
 Average RFU Standard Deviation 3 X Standard Deviation Baseline 
Active 
SNP 
55 17 51 55 + 51=106 
Inactive 
SNP 
16 12 36 16+36=53 
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Forensic Sciences to further analyze the C2E2 amplicon region within the THCA synthase gene 
for further sequence information.  The parameters for amplicon sequencing using the Ion Torrent 
Personal Genome Machine® (PGM™) (Life Technologies, Carlsbad, CA) were those described in 
the manufacturer’s instructions.(43)  Data was analyzed using the Integrated Genomics Viewer 
(Broad Institute, Cambridge, MA) program.(44)  
Chemical Analysis via GC/MS 
 Preparation of Chromatography 
 Chemical analysis of cannabinoids was performed using gas chromatography coupled 
with mass spectrometry (GC/MS) on an Agilent 6890 GC (Agilent, Santa Clara, CA) coupled 
with an Agilent 5973 mass spectrometer (Agilent, Santa Clara, CA).  For optimum separation of 
cannabinoids using gas chromatography-mass spectrometry, the Rxi®-32Sil MS fused silica 
column was selected (Restek, Belfonte, PA).  Suggested parameters for gas chromatography that 
were provided by Restek were further optimized in house and included injection volume and split 
ratio, injection liner, injection temperature, oven temperature, carrier gas, flow rate, and detector 
parameters.  Methapyrilene (MePy; Sigma Chemical Co., St. Louis, MO) was chosen as the 
internal standard and was mixed with samples at 50 µg/mL concentration in methanol (VWR 
International, Radnor, PA). 
 Identification of ions for each of the three cannabinoids [THC, CBD, and Cannabinol 
(CBN)] was accomplished by running known drug standards (Cerilliant, Round Rock, TX) and 
choosing ions from their respective mass spectra.  Cannabinoid concentrations were determined 
using a standard curve constructed by analyzing signal strengths produced by known amounts of 
THC, CBD, and CBN on the GC/MS.  Standard curves were produced using an eight point curve 
ranging in concentration from 200 µg/mL to 1.063 µg/mL of each cannabinoid.  For each 
standard at each concentration, a ratio of the signal produced by the drug versus the signal 
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produced by the internal standard was determined; this normalized each injection of sample into 
the GC/MS based upon a constant methapyrilene standard.  Standard curves routinely exhibited 
R2 values of >0.99.   
 Cannabinoid concentrations in unknown samples were estimated by plotting the ratio of 
THC, CBD, or CBN to the internal standard on the standard curve.  Included with each GC/MS 
run were three controls that were produced by diluting reference cannabinoid standards to 
concentrations of 200µg/mL, 50 µg/mL, and 6.25 µg/mL representing high, medium, and low 
concentration controls.  The lot numbers of the cannabinoids used for the controls were different 
from those of the standard curves, thus ensuring that the instrument was performing correctly 
between sampling.  A limit of detection was calculated by averaging the total background noise 
for each negative control sample and multiplying the value by three.  The limit of quantitation 
was also calculated by multiplying the same background noise average by 10.  These limits set 
the minimum value for detection and quantitation of drugs in the C. sativa samples. 
 Cannabinoid Extraction from Plant Material 
 Using an analytical scale and sterile forceps, 15 mg of plant material from seized drug 
samples were weighed and placed into labeled 0.6 µL microfuge tubes.  These weights were 
recorded on the evidence log described previously.  To extract the cannabinoids from the plant 
material, 250 µL of 50 µg/mL MePy/MeOH was added to each sample.  The tubes were placed in 
a heat block at 65 °C for 30 minutes.  After incubation, a hole was pierced in the bottom of each 
0.6 mL tube that was then placed into a labeled 1.8 mL microfuge tube.  The samples were 
centrifuged at 10,000 x g for 3 minutes to collect the liquid extract while the plant material 
remained in the 0.6 mL microfuge tube.  Following centrifugation, 4 µL of each extract was 
placed into a labeled GC-MS vial with 196 µL of 50 µg/mL MePy/MeOH. Using this approach it 
was possible to ultimately calculate the percent cannabinoid based upon the weight of the plant 
material extracted. 
30 
 Chemical Analysis 
 To ensure that the instrument is prepared to run samples, the mass spectrometer was 
autotuned prior to running samples.  Methanol was added to the appropriate vial for cleaning 
between each sample.  A blank of methanol was also run prior to samples to ensure the column 
was free and clear of any contaminants.  A negative control consisting of 50 µg/ml MePy/MeOH 
was run as well to ensure that methapyrilene was selected as internal standard and to measure the 
amount of background noise for each cannabinoid.  Three unique ions were selected for each 
cannabinoid based on abundance in the mass spectrogram.   
 Batches were input based on sample name, vial number, and date of run.  Because the 
instrument is set up with an auto injector, each set of injections allowed for eight vials.  One 
standard curve was run prior to any samples for quantification of cannabinoids.  A control was 
run as vial 1 for each set, and samples were run in vials 2-8.   
Statistical Analysis 
 Correlation Studies 
 Correlation statistics were computed by Dr. Mark Payton of the Oklahoma State 
University Statistics Department to assess the possible correlation between the THCA SNP 
activity and cannabinoid composition of C. sativa samples.  First, an analysis of variance, or 
ANOVA was performed to compare the percentage of THC from GC-MS data with 
characteristics of three SNPs from SNaPshot® data.  In order to perform the ANOVA, numerical 
values were used in place of homozygous-active, heterozygous, and homozygous-inactive 
nominal descriptions.  Thus, homozygous-active samples were numbered 0, heterozygous 
samples were numbered 1, and homozygous-inactive samples were numbered 2.  Then, the ratio 
of active/inactive peak height RFU was computed from SNaPshot® results (discussed previously).  
To determine if a correlation was present between these values and percent THC, the potential 
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correlation between each possible combination of RFU value ratio at a given SNP to percent THC 
obtained from a sample was calculated using Pearson’s coefficient.  A correlation would 
determine that percent THC could be predetermined based on genetic analysis via SNaPshot® 
within C. sativa samples. 
Summary 
 Using SNaPshot® analysis and gas chromatography-mass spectrometry, the presence of 
the polymorphisms and THC content within C. sativa samples can be determined.  This 
determination could potentially show that a correlation exists between cannabinoid content and 
genetic variations within C. sativa.  This research could potentially provide a resource to growers, 
providers, dispensaries, and users of medicinal marijuana to know the quality of medicinal 
marijuana plant product based on the analysis of seeds, pollen, and immature plant material.  The 
knowledge gained from this study could save these individuals time spent growing plants as well 
as stress from the lack of knowledge about their current product.  It could also optimize treatment 
of illnesses using medicinal marijuana, giving the individuals affected by those illnesses more 





RESULTS AND INTERPRETATION 
 
Overview 
 Investigative methods of genetic and chemical analysis of Cannabis sativa samples 
discussed previously include SNaPshot® analysis, amplicon sequencing, and gas 
chromatography-mass spectrometry.  The SNaPshot® reactions were performed on separate days 
prior to GC-MS for each set of samples.  The results and interpretation of results follow. 
Genetic Analysis 
 Results of SNaPshot® 
 In order to examine the results from the SNaPshot® reactions, a brief review of the 
functions of the process is necessary.  Primers 8F and 9F designed by Rotherham and Harbison 
are forward primers that are complimentary to the non-coding sequence of the THCA synthase 
gene.(17)  Contrarily, primers 16R and 17R are reverse primers that are complimentary to the 
coding strand of the THCA synthase gene.  A graphic displayed in Figure 3 provides a visual 





 The SNaPshot® mastermix contains dideoxynucleotides (ddNTPs) that allow the 
sequence to extend one extra nucleotide after the end of the primer.  Within active (wild-type) 
samples, a dideoxythymine is extended from the forward primers.  Since the forward primers are 
complementary to the non-coding strand, a thymine is incorporated within the nucleotide 
sequence.  Similarly, within active (wild-type) samples, a dideoxythymine is extended from the 
reverse primers.  However, because the reverse primers are complementary to the coding strand, 
an adenine is incorporate within the nucleotide sequence.  Because SNPs are changes within the 
DNA sequence, the inactive samples that contain SNPs at the predetermined positions incorporate 
nucleotides other than the active (Table 4). 
 
 
Figure 3: Primer Alignment in C2E2 Amplicon of THCA Synthase Gene. 
 
 
The visual representation adapted from Rotherham and Harbison shows the THCA Synthase 
gene spanning across 1688bp of the C. sativa genome.(17)  The C2E2 amplicon is located 738 
bp downstream from the THCA synthase start codon.  The locations of the C2 and E2 primers 
discussed in the methodology section are shown here.  The SNP positions within the gene are 
also demonstrated from their individual primer locations.  The forward (F) SNP primers 8F 
and 9F are complimentary to the non-coding strand, while the reverse (R) SNP primers 16R 
and 17R are complimentary to the coding strand. 
THCa 
nt 1 C2 F 
738 bp 
17R 16R 
887bp  953bp 
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nt 1688 
        8F  9F 




16R 9F 8F 17R 
  
    
 The results of the SNaPshot® reactions were visualized in GeneMapper (version 3.2) 
genetic analysis software.  Examples of homozygous-active, heterozygous, and homozygous-
inactive chromatograms are shown in Figures 4, 5, and 6 respectively.  
 
 
    Table 4: THCA Synthase SNP Nucleotide Incorporation 
 8F 9F 16R 17R 
Active Thymine Thymine Adenine Adenine 
Inactive Guanine Adenine Thymine Guanine 
 





The red peaks depict the extension of a thymine from the 3’ end of the 
primers discussed previously within the SNaPshot® reaction, 
demonstrating that the sample types active for these four SNP positions 
within THCA synthase. 
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The multicolored peaks (other than red in Figure 4) depict the extension of an 
adenine for green, a guanine for blue, and a cytosine for yellow (visualized as 
black) in place of other nucleotides within the template strand in the 
SNaPshot® reaction.  The results demonstrate that the sample types 
heterozygous for these four SNPs within THCA synthase. 
The multicolored peaks depict the extension of an adenine for green, a 
guanine for blue, and a cytosine for yellow (visualized as black) in place of 
other nucleotides from the template in the SNaPshot® reaction.  Because the 
chromatogram is lacking the active thymine (red) peaks, the results 
demonstrate that the sample types homozygous-inactive for these four SNPs 
within THCA synthase. 
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 Once the chromatograms were analyzed considering the optimized analytical threshold of 
50 RFU, the relative fluorescent units (RFU) for each SNP position of the samples were recorded.  
These units were then assessed by forming a ratio of active to inactive peak height RFU.  The 
samples with a ratio of 0 were determined to be homozygous-inactive (I), the samples with a ratio 
between 0 and 1 were heterozygous (A/I), and the samples with a ratio of 1 were determined to be 
homozygous-active (A).  With 75 C. sativa samples analyzed, only three samples typed as 
homozygous-active.  Furthermore, out of 75 samples analyzed, only four samples typed as 
homozygous-inactive.  Therefore, 68 samples were determined to be heterozygous for active and 
inactive THCA synthase single nucleotide polymorphisms.  As mentioned in the methodology, 
samples that typed homozygous-active depicted only active peaks at all four SNP positions; 
samples that typed heterozygous depicted both active and inactive peaks at all four SNP 
positions, and samples that typed homozygous-inactive depicted only inactive peaks at all four 
SNP positions.  Therefore, there were no mosaic representations within the results in which a 
sample would contain only an active peak at one SNP position and only an inactive peak at 
another SNP position.  The lack of mosaic results reflects that the four SNPs within the THCA 
synthase gene act as a uniform haplotype. 
 Results of THCA Synthase Amplicon Sequencing 
 In order to analyze the SNPs of the 400 bp amplicon, the THCA synthase gene was 
selected as the reference gene from GenBank (AB057805.1).  The samples processed with 
genomic sequencing using the Ion Torrent PGM platform were selected based on zygosity.  
Seven samples were sequenced and processed through IGV software, including active samples 
#5725 and #6922; heterozygous samples #0565, #0777, #1688, and #5725; and homozygous 
samples #6043, and #7436 (Appendix A).  
 When visualizing the entire THCA synthase gene, a remarkable predominance of single 








comparison with THCA synthase-active samples.  Figure 6 below displays the sequencing 
alignments of two samples that typed as inactive and active for the THCA synthase gene in 
SNaPshot®.  
 






 All of the SNPs that were reported from Rotherham and Harbison were present in each 
homozygous-inactive samples processed on Ion Torrent PGM.(17)  Figure 7 shows examples of 
active and inactive samples within the C2E2 amplicon region of the THCA synthase gene. 
IGV allows visualization of sequencing alignments to be viewed simultaneously.  Seen 
above is the alignment of the THCA synthase gene.  The top half shows the alignment of a 
THCA-synthase inactive C. sativa sample, as determined by SNaPshot®.  The 
multicolored bands present within the sequences demonstrate the predominance of SNPs 
in inactive samples.  On the other hand, a THCA-synthase active C. sativa sample is 














 The results from the amplicon sequencing allowed for the quantitation of SNPs 
within a sample.  Based on the number of replicate alignments, the percentage of each 
nucleotide present in the replicate strands sequenced on the Ion Torrent PGM can be 
determined for each position in the sequence.  Figure 8 displays the alignment of an 
active sample and an inactive sample with the percentages shown for the 9F SNP 
position.  
As seen with the THCA synthase genomic sequencing results, the inactive samples retain 
the single nucleotide polymorphisms within the genome.  All four SNPs analyzed were 
present in each inactive sample, along with a multitude of other SNPs.  The active samples, 
however, demonstrate wild-type sequence alignments, shown by the lack of SNPs at the 
four positions within the sequence.  The four vertical red bars at the top of the figure 
indicate the SNP positions within the C2E2 amplicon as reported by Rotherham and 
Harbison.(17) 
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 Use of IGV also allows for the translation of the reading frame from the DNA sequence 
to the amino acid sequence.  As such, the active and inactive amino acid sequences are displayed 
(Table 5).  Changes in the amino acid sequence shown below are caused by the SNPs. 
   Table 5: Changes in Amino Acid Sequence at SNP Positions 





















The percentage of nucleotides present in the replicates for the 16R position is shown for the 
active (6922) and inactive (6043) samples above.  The presence of adenine for the active is 
displayed at 96%, whereas the inactive sample counts adenine at 3%.  However, the inactive 
sample presents thymine at 96%, showing the difference in quantities of SNPs and zygosity. 
6922-THCA Synthase Active 6043-THCA Synthase Inactive 
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 The nucleotide sequence in Table 5 at the 9F SNP position reflects the established 
thymine to adenine polymorphism, as well as the thymine to cytosine polymorphism.  The 
thymine to cytosine transition is present in all inactive samples sequenced on Ion Torrent PGM. 
Gas Chromatography-Mass Spectrometry 
 Results of Gas Chromatography-Mass Spectrometry 
 In order to evaluate the results of GC/MS, the values of limit of detection (LOD), limit of 
quantitation, (LOQ), and the standard curves were first analyzed.  In order to calculate the LOD 
and LOQ, the measurement of total concentration was added from each ion for each cannabinoid 
from the three negative controls (aliquots of 50µg/mL methapyrilene in methanol).  These values 
were then averaged for each cannabinoid.  The LOD and LOQ calculations are shown in Table 6 
below.  These limits were set to establish the minimum values to determine if the drugs within the 
samples were quantifiable. 
 
 
   Table 6: Limit of Detection and Quantitation Calculations (in absorbance units) 
 
 CBD THC CBN 
Average Background Noise Detection 637.5 450 800 
Limit of Detection (3 times average) 1912.5 1350 2400 
Limit of Quantitation (10 times average) 6375 4500 8000 
 
  
 The standard curves discussed in the methodology section enabled the quantitation of 
cannabinoids within the samples.  Three curves were made, and the values of each cannabinoid 
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for each concentration were averaged to compare with C. sativa samples.  An average standard 
curve is displayed in Figure 10. 
 
 In order to ensure that the GC-MS was operating correctly between runs, three 
concentration controls were used for each cannabinoid and included with each batch of samples 
analyzed.  Table 7 shows the concentration of cannabinoids calculated from plotting the ratio of 
cannabinoid/internal standard in the standard curve formula of each cannabinoid. 
 
  Figure 10: GC-MS Standard Curve for CBD, THC, and Cannabinol 
 
 
y = 0.0067x - 0.0346
R² = 0.9955
y = 0.0242x - 0.1156
R² = 0.9969











































Above are the plotted standard curves for each cannabinoid, expressed by color depicted in 
the legend.  The known concentration was compared to the ratio of 
cannabinoid/methapyrilene concentration taken from the mass spectrometer output.  This 
created the data in the form of a standard curve, with linearity R2 values depicted above 0.99.  
The function formula is used to compute the concentration of each cannabinoid in unknown 
samples.  The error bars in each curve represent the potential error, calculated by one standard 
deviation for each data point. 
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 Using the linear curve equation from the standard curves on the ratio of cannabinoid to 
internal standard from the MS output was input for X.  This value was then multiplied 50 for the 
dilution of extracts in MePy/MeOH, multiplied by 0.25 for the initial 250 µl extraction volume, 
and divided by 15000 for the initial 15 mg weight of sample.  The final value was multiplied by 
100 to produce a percentage.  An example of a sample calculation is shown n Figure 11 for the 
percentage of THC in a sample. 
 
 
  Table 7: GC-MS Cannabinoid Controls 
 Day 1 Day 2 Day 3 
Known CBD THC CBN CBD THC CBN CBD THC CBN 
200 
µg/mL 
185.05 239.70 192.31 195.98 239.70 192.31 205.40 205.4 207.67 
50 
µg/mL 
43.96 45.03 44.12 45.85 45.03 44.12 43.08 46.73 43.68 
6.125 
µg/mL 
7.98 8.67 8.90 7.56 8.67 8.90 8.19 8.73 8.54 




(from Figure 10) 












 =156.2089552   
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 Because C. sativa is often characterized in terms of the THC/CBD ratio, the ratios for 
THC and CBD were computed across all samples (Appendix B).  Since the genetic analysis 
pertained to the investigation of THCA synthase, the primary focus of chemical analysis involved 
only THC.  The percentages of THC within a sample ranged from 0.9% to 18% THC with an 
average of 6.54% (Figure 12). 
 


































Displayed is a representation of the ranges of THC percentage within C. 
sativa samples, sorted from the lowest to highest concentration.  The 
percentage of THC within 75 illicit C. sativa samples from Tulsa Police 
Department seizures ranged from 0.9% to 18%, shown in blue.  The 
average percentage THC was 6.54%, shown in red. 
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 In comparing the results from the gas chromatography with results from SNaPshot®, the 
comparison demonstrated that the majority of samples were heterozygous for SNaPshot®, as 
described previously.  Figure 13 below shows the visual representation of comparisons between 
SNP activity and percentage THC.   
 


































Within SNaPshot, the samples that typed as THCA Synthase active were 
labeled 0, the samples that typed as heterozygous were labeled 1, and the 
samples that typed as THCA synthase inactive were labeled 2.  In comparing, 
the highest percentage of THC in the active samples was 7.5% and the lowest 
percentage of THC within the inactive samples was 7.7% (Appendix A). 
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 Since the THC activity in theory should correlate with percentage of THC, it is of 
importance to note that the samples that typed as homozygous-inactive for THCA synthase had 
slightly higher percentages of THC than the samples that typed homozygous-active for THCA 
synthase, shown in Table 8. 
 
Table 8: Comparison of SNP Activity with Percent THC 
Sample SNP Activity %THC (µg/mL) 
9961 0 6.04 
6922 0 6.67 
5725 0 7.51 
9944 2 7.71 
6043 2 8.28 
7436 2 8.38 




 Results of Analysis of Variance 
 The ANOVA comparison of percent THC to SNP activity showed that there is no 
statistically significant difference in the percent THC of active (0), heterozygous (1), or inactive 
(2) samples.  ANOVA results are depicted in Figure 14. 
 
Above shows a summary of comparisons of only samples that typed as active or inactive 
for THCA Synthase from SNaPshot results with %THC for each sample.  Samples that 
were active were numbered 0, whereas samples that were inactive were numbered 2.  
Notice that a higher percentage of THC is present in THCA synthase Inactive samples. 
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Figure 14: ANOVA Results Comparing Percent THC and SNP Activity 
                        
Type 3 Tests of Fixed Effects 
Effect Numerator DF 
Denominator 
DF 
F Value Pr > F 
SNP 2 72 0.57 0.5687 
   
Least Squares Means 
Effect SNP Average % THC Standard Error 
SNP 0 (Active) 6.7405 2.2033 
SNP 1 (Heterozygous) 6.4250 0.4628 






 Results of Correlation Statistics 
 In order to asses which variables contributed to potential variation or correlation, the 
RFU ratios of each individual SNP position was calculated, as discussed in the methodology 
section.  Using simple statistics, the mean, standard deviation, sum, minimum, and maximum 
values between 16 variables/combinations of variables and percentage THC were calculated.  
These values were used to calculate the Pearson’s correlation coefficient for each variable.  Not 
one variable or combination of variables revealed a statistically significant P value (Table 9).   
 
 
The ANOVA results above compared the percentage THC across all SNP positions.  Though 
it may seem like the difference between 8.5118 from SNP 2 and 6.4250 and 6.7405 from the 
other SNPs is large, the P value of 0.5687 demonstrates that there is no statistically 
significant difference between the average percentages of THC of the SNPs. 
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Table 9: Pearson’s Correlation Coefficient Results 
 
Pearson’s Correlation Coefficients 
N=75 
Variable H0: Rno=0 Prob > |r| 
PCT THC 1.00000  
PCT 16 0.04368 0.7098 
PCT 9 0.04673 0.6906 
PCT 8 0.03796 
 
0.7464 
PCT 17 0.00241 0.9836 
PCT ALL 0.03352 0.7753 
PCT 16, 9, 8 0.04291 0.7147 
PCT 16, 9, 17 0.03188 0.7860 
PCT 16, 8, 17 0.02869 0.8070 
PCT 9, 8, 17 0.03017 0.7972 
PCT 16, 9 0.04544 0.6987 
PCT 16, 8 0.04084 0.7280 
PCT 16, 17 0.02344 0.8418 
PCT 9, 8 0.04237 0.7181 
PCT 9, 17 0.02596 0.8251 




Pearson’s correlation coefficient demonstrates either negative correlation between two variables 
(0) or a positive correlation between two variables (1).  The results of the Pearson’s coefficient 
calculations demonstrate that there was no statistically significant correlation between percentage 
THC between and within all SNPs within a sample, between any SNP position within a sample, 
or between combinations of SNPs within a sample, or between any sample.
The results from Pearson’s correlation coefficients above demonstrate that there is no 
statistically significant correlation between percentage THC and any individual/combination of 





DISCUSSION AND CONCLUSIONS 
 
Overview: 
 The principle goal of the current investigation was to determine if there was correlation 
between genetic variations within THCA synthase, or genotype, and of THC, or chemotype, in 
drug-type Cannabis sativa plants, also known as marijuana.  The rationale for the study was 
derived from an article that concluded that THC composition within the plant could be 
determined from genetic analysis.(17)  By expanding the methodology, the initial findings of other 
research was improved upon.  A more in-depth discussion of each particular analytical method 
follows. 
Cannabis sativa Sampling 
 Although permission was granted to obtain and work with C. sativa samples that were 
selected from TPD seizures, the original source of cannabis was subject to bias.  Because illicit 
C. sativa, also known as marijuana, typically refers to samples with higher THC percentage, the 
selection of samples taken from the illicit market biased those samples to have higher percentages 
of THC.(27)  Prior knowledge about source of growth, geographical origin, or absolute age of the 
samples was also unavailable and may have subjected results to bias.  Furthermore, unlike the 
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study by Rotherham and Harbison, samples within the current study were not categorized based 
on GC-MS results prior to testing via SNaPshot® analysis.(17) 
 Another sampling factor that may have contributed to inconsistent results was the lack of 
negative control.  Experimental design typically includes a negative control which is substance 
that behaves similar to the sample being tested, but lacks proper characteristics to produce results.  
In this experiment, a form of C. sativa known to lack high percentages of THC, called hemp, 
would serve as a promising negative control.  This non-drug type of C. sativa was also used as a 
negative control in the article by Rotherham and Harbison.(17)  However, in order to obtain a 
hemp sample from a legal source such as law enforcement, a DEA licensure is required.  This 
license remains pending within OSU Forensic Sciences laboratories, and as such hemp samples 
were unavailable for chemical testing.  DNA from hemp was available however, as it is possible 
to purchase hemp seeds for a food snack.(45)  It should be noted that the genomic DNA from hemp 
seeds represents a population of molecules from different meiotic events as the material extracted 
was seeds.  Since each seed is an individual plant, each would represent a different combination 
of genetic markers. 
SNaPshot® Analysis 
 The method of the SNaPshot® reaction was altered in order to optimize results for the 
study.  The occurrence of off-scale peaks in the early genetic analyses necessitated further 
dilution of initial C2E2 PCR products.  Organic phenol:chloroform:isoamyl alcohol extraction 
was used in lieu of methods by Rotherham and Harbison because of required laboratory protocols 
within the student forensic DNA laboratory.  The DNA was quantified using a Nanodrop 
spectrophotometer to ensure adequate amount of DNA was present for initial PCR.  However, the 
concentration of DNA was not equivalent across all samples, which may have contributed to the 
need for various levels of dilution. 
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 From the SNaPshot® results, the samples that typed as heterozygous varied in 
characteristics of the SNaPshot® profile in terms of the peak heights (Appendix A).  Certain 
samples presented with higher active peaks than inactive, and vice versa.  These results are 
demonstrated in the ratios of active/inactive peak height used for statistical analysis (Appendix 
A).  Although samples were characterized only as active, heterozygous, or inactive, variations 
within level of activity could result in division of samples into subcategories heterozygous-active 
or heterozygous-inactive based upon the RFU ratios in the different heterozygous genotypes.  The 
occurrence of subsets within heterozygote samples could be a result of possible polyploidy. 
 Polyploidy is the term used when a typically diploid organism contains, for example, one 
(triploid) or two (tetraploid) extra sets of chromosomes.  Aneuploidy refers to organisms that 
contain an abnormal number of chromosomes; as such, these organisms may lack a chromosome 
or have an extra chromosome.(46)  The occurrence of polyploidy within C.  sativa has been 
attributed to the use of clonal propagation, which is the reason “why it is not possible to apply 
Hardy–Weinberg biostatistics.”(47)  Another potential cause of polyploidy and aneuploidy within 
C. sativa plants could be the use of biochemical modification.  One example of modification 
includes soaking seeds or young plant roots in colchicine, that prevents cytokinesis in meiosis and 
results in the increase of chromosomes within the cell.(46)  The occurrence of polyploidy and 
aneuploidy will obviously affect typical diploid zygosity, therefore preventing the use of 
traditional Hardy-Weinberg understanding of allelic balance and also affecting possible 
correlations between genotype and chemotype in marijuana plants.   
Amplicon Sequencing Analysis 
 Along with SNaPshot® heterozygote ratios, the variation within samples that type as 
heterozygous for THCA synthase SNPs was also demonstrated in the results from the Ion Torrent 
PGM genomic sequencing.  The percentages of nucleotides within heterozygote SNPs varied 
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across multiple SNP positions.  One of the sequenced samples revealed a composition of 32% 
adenine and 68% guanine for the 8F SNP position.  In some heterozygotes, the ratios were closer 
to 75%:25% for the different SNPs.  If the sample typed as a true heterozygote per Hardy-
Weinberg equilibrium, the percentages would appear closer to 50%:50%.   
 The polyploidy issue within the tested C. sativa samples could not be addressed in the 
current research since the flowering buds of the plant had already been dried.  If the plants had 
been living or in better condition, karyotyping methods could have been employed to determine 
the number of chromosomes for the plant.(48)  The determination of number of chromosomes 
within samples could have resolved much of the uncertainty regarding zygosity within the C. 
sativa plants investigated. 
GC-MS Analysis 
 The matrix effects of THC, CBD, and CBN were originally tested using oregano as a 
negative control.  However, use of oregano would not correlate with a negative C. sativa sample, 
since only C. sativa plants may have other cannabinoids that effect the composition of the THC, 
CBD, or CBN.  Because non-drug C. sativa, or hemp, was unobtainable for chemical testing, the 
possibility of testing true matrix effects was not possible within Oklahoma State University 
School of  Forensic Sciences laboratories.  The Restek column that was used separates six total 
cannabinoids.  Without using a true negative control to test for matrix effects, it was not possible 
to determine if other cannabinoids such as cannabichromene affected the results of THC, CBD, or 
CBN.   
 When observing the values of low controls, the 6.125 µg/mL measurements fell outside 
the range of +/-20% reproducibility.  After the first day that control results were analyzed, an 
additional low control at 12.5 µg/mL was added.  Results for this control were within acceptable 
limits. 
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 It is also important to highlight factors that influence THC within C. sativa.  The report 
by the UNODC states that THC undergoes degradation over time, and can degrade in certain 
environmental factors including light, air, and humidity.(11)  Therefore, the true concentration of 
THC within the samples in the current study could have been affected by these factors because 
the storage conditions and age of samples prior to TPD seizure were unknown. 
Correlation Analysis 
 The cannabinoid biosynthesis within C. sativa remains unclear.  There is no conclusive 
evidence stating that the THCA synthase gene is the only means of synthesizing THC within C. 
sativa.  The gaps within the C. sativa genome that remain to be investigated could potentially lead 
to more knowledge about cannabinoid biosynthesis.  Thus, other undetermined factors may 
influence cannabinoid biosynthesis and accordingly production of THC.   
 The addition of SNPs within the THCA synthase gene other than those investigated here 
would increase the likelihood of determining activity and potential correlation of production of 
THC.  Although the four SNPs investigated here did not correlate with THC production, other 
SNPs that were not investigated could also lead to deactivation of the THCA synthase gene via 
changes in the amino acid sequence.  Until all of the SNPs within the THCA synthase gene are 
investigated simultaneously, the correlation between SNPs within the THCA synthase gene and 
THC concentration cannot be determined with 100% certainty. 
Comparison of Results 
 Although the initial interest in the current study was a derivative of the Rotherham and 
Harbison study, the evidentiary samples selected by Rotherham and Harbison were from New 
Zealand, which may differ dramatically from the samples of the United States.(17)  The study by 
Rotherham and Harbison reveals numerous errors in their results.   
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 First, the authors state that only 51 of the 75 drug-type C. sativa samples were quantified 
via GC-MS.  However, their results show that each sample had a concentration of THC that fell 
within certain ranges; these results are confounding with their previous statement.  Although the 
authors state the presence of THC was confirmed via thin-layer chromatography for samples that 
were not quantified via GC-MS, this screening confirmation may not adequately quantify a 
concentration of THC, and should not be reported as a concentration. 
 Secondly, the authors describe their results from SNaPshot® in terms of SNP position 
with according nucleotide change and change in amino acid sequence.  Rotherham and Harbison 
failed to include the change in amino acid sequence for the 17R SNP position.  They also 
erroneously reported the amino acid change for both the 8F and 9F SNP positions.  Their results 
state that 8F, at 1035 bp, changes a thymine to a guanine, which corresponds accurately with the 
results in the current study.  However, they state that this change results in a change in the amino 
acid sequence from a Phenylalanine to a Leucine.  The codon for Leucine lacks a guanine 
altogether.  For the 9F position, the authors state that the nucleotide sequence changes a thymine 
in the active form to a adenine in the inactive form, which also corresponds accurately with the 
results in the current study.  Yet the authors state that amino acid change for the 9F SNP position 
is from lysine to arginine, which is also incorrect.  Lysine codons lack a thymine.   
 Lastly, the results of Rotherham and Harbison are confounding because the authors did 
not include a description of determination of peak variation within SNP positions, or a description 
of how they determined a baseline threshold.  They did state that there was an artifact in the 16 
SNP position within every SNaPshot® reaction.   
 In comparing results, the majority of the samples by Rotherham and Harbison were 
heterozygous, which is similar to the current study.  It is difficult to compare results with the 
study by Rotherham and Harbison since the authors included the 15 hemp or non-drug type C. 
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sativa samples within their results, whereas the current study only analyzed samples from forensic 
seizures.  It would be interesting to compare results if they had separated their results into the 
samples that were previously determined to be drug-type. 
Possible Future Studies 
 A potential consideration for future studies would be to take samples directly from 
mature plants to test for ploidy and to continue with SNaPshot® analysis once diploid zygosity 
was determined.  In order to confidently determine these factors, it would be best to grow plants 
of known genotype under the same conditions and harvest the mature female inflorescence at the 
same time.  Incorporation of all of the previously determined SNPs within the THCA synthase 
gene would also create a more definitive determination of amino acid sequence and subsequent 
level of THCA synthase activity.  It would be preferable to sequence all of the samples that were 
processed with SNaPshot®.  Funding in the sequencing area of the School of Forensics Science at 
OSU was limited, thus further sequencing of samples was not possible.  Other options for genetic 
analysis would include the investigation of the CBD synthase gene within C. sativa samples. 
Conclusion 
 The purpose of the present study was to investigate the potential correlation between 
percentage of Δ9-tetrahydrocannabinol and zygosity of single nucleotide polymorphisms (SNPs) 
within the THCA synthase gene.  The use of the SNaPshot® minisequencing kit and gas 
chromatography-mass spectrometry allowed analysis of these components.  Correlation statistics 
were performed between the percentages of THC from GC-MS data and the zygosity of SNP 
positions from SNaPshot® data.  The statistical results showed that there was no correlation 
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 The following appendices contain raw data from analyses.  Appendix A contains data 
from SNaPshot® analysis, wherein the zygosity column refers to homozygous-active samples 
numbered as 0, heterozygous samples numbered as 1, and homozygous-inactive samples 
numbered as 2.   Appendix B contains data from GC-MS Analyses, including Standard Curves, 





Sample 16I 16A Ratio A/I 9I 9A Ratio A/I 8I 8A Ratio A/I 17I 17A Ratio A/I Average SNP ratio Zygosity* 
254 923 443 0.3243045 3097 776 0.2003615 1626 520 0.2423113 551 475 0.462963 0.307485064 1 
255 900 333 0.270073 2958 582 0.1644068 1794 428 0.1926193 612 443 0.4199052 0.261751062 1 
275 328 233 0.4153298 1177 432 0.2684897 719 317 0.3059846 215 302 0.5841393 0.393485834 1 
365 213 888 0.8065395 462 1823 0.7978118 247 1152 0.8234453 133 1051 0.8876689 0.828866391 1 
367 237 524 0.6885677 616 932 0.6020672 406 750 0.6487889 160 583 0.7846568 0.681020145 1 
452 629 250 0.2844141 2116 440 0.172144 1308 327 0.2 431 333 0.4358639 0.273105489 1 
466 587 194 0.2483995 1975 356 0.1527242 1191 262 0.1803166 396 278 0.4124629 0.248475784 1 
565 429 386 0.4736196 1106 667 0.3761985 742 545 0.4234654 275 435 0.6126761 0.471489911 1 
597 98 661 0.8708827 206 1304 0.8635762 137 1025 0.8820998 50 749 0.9374218 0.888495126 1 
661 361 452 0.5559656 1206 851 0.4137093 666 573 0.4624697 222 502 0.6933702 0.531378686 1 
777 511 75 0.1279863 1726 129 0.0695418 1050 96 0.0837696 332 105 0.2402746 0.13039309 1 
866 209 137 0.3959538 565 200 0.2614379 361 164 0.312381 152 164 0.5189873 0.37218999 1 
956 495 314 0.3881335 1609 583 0.2659672 978 422 0.3014286 359 421 0.5397436 0.373818203 1 
1072 509 195 0.2769886 1650 336 0.1691843 994 251 0.2016064 363 264 0.4210526 0.267207996 1 
1187 452 330 0.4219949 1524 684 0.3097826 939 501 0.3479167 317 443 0.5828947 0.415647224 1 
1220 1117 618 0.356196 3676 1142 0.2370278 1943 728 0.2725571 631 655 0.5093313 0.343778033 1 
1250 439 404 0.4792408 1499 801 0.3482609 956 588 0.380829 298 528 0.6392252 0.461888968 1 
1365 613 661 0.5188383 2015 1244 0.3817122 1074 801 0.4272 380 716 0.6532847 0.495258789 1 
1497 1186 866 0.4220273 4253 1718 0.287724 2303 1127 0.3285714 706 955 0.5749548 0.403319391 1 
1688 289 299 0.5085034 859 578 0.4022269 535 422 0.4409613 223 406 0.645469 0.49929015 1 
1697 876 555 0.3878407 3189 1017 0.2417974 1699 677 0.2849327 533 600 0.5295675 0.361034571 1 
1778 330 230 0.4107143 1026 431 0.2958133 643 325 0.3357438 234 295 0.557656 0.399981839 1 
1868 142 224 0.6120219 479 406 0.4587571 283 298 0.5129088 109 285 0.7233503 0.576759488 1 
1991 217 102 0.3197492 604 151 0.2 397 126 0.2409178 131 102 0.4377682 0.29960881 1 
64 
Sample 16I 16A Ratio A/I 9I 9A Ratio A/I 8I 8A Ratio A/I 17I 17A Ratio A/I Average SNP ratio Zygosity* 
2227 1169 681 0.3681081 4048 1247 0.2355052 2125 796 0.2725094 722 730 0.5027548 0.344719384 1 
2251 642 213 0.2491228 2241 360 0.1384083 1367 265 0.1623775 411 272 0.398243 0.237037902 1 
2255 1023 260 0.20265 3375 426 0.1120758 2123 315 0.1292043 670 335 0.3333333 0.194315852 1 
2517 840 327 0.2802057 2655 581 0.1795426 1642 431 0.2079112 590 435 0.4243902 0.273012446 1 
2761 594 250 0.2962085 1979 452 0.1859317 1234 342 0.2170051 416 334 0.4453333 0.286119664 1 
3056 416 317 0.4324693 1293 585 0.3115016 817 431 0.3453526 308 421 0.5775034 0.416706724 1 
3579 323 116 0.2642369 1054 216 0.1700787 664 158 0.1922141 214 156 0.4216216 0.262037844 1 
4344 510 301 0.3711467 1789 625 0.2589064 1134 461 0.2890282 355 404 0.5322793 0.36284016 1 
4606 628 119 0.1593039 2208 202 0.0838174 1390 149 0.0968161 410 151 0.2691622 0.152274909 1 
5075 150 251 0.6259352 452 528 0.5387755 291 386 0.5701625 109 336 0.7550562 0.622482333 1 
5546 587 202 0.2560203 2017 378 0.1578288 1282 284 0.1813538 384 266 0.4092308 0.251108406 1 
5725   283 1   654 1   483 1   383 1 1 0 
5774 218 151 0.4092141 507 254 0.3337714 323 197 0.3788462 122 185 0.6026059 0.431109366 1 
5888 576 187 0.2450852 2036 373 0.154836 1259 268 0.1755075 416 256 0.3809524 0.239095283 1 
5931 221 150 0.4043127 703 292 0.2934673 428 213 0.3322933 156 195 0.5555556 0.396407213 1 
6043 528   0 1995   0 1254   0 360   0 0 2 
6264 460 268 0.3681319 1666 577 0.2572448 1028 421 0.2905452 321 366 0.5327511 0.362168231 1 
6352 714 189 0.2093023 2447 329 0.1185159 1480 243 0.1410331 501 244 0.3275168 0.199092009 1 
6361 270 212 0.439834 971 461 0.3219274 588 331 0.3601741 200 297 0.5975855 0.429880254 1 
6922   526 1   1381 1   967 1   761 1 1 0 
7326 299 255 0.4602888 960 496 0.3406593 654 382 0.3687259 210 312 0.5977011 0.441843792 1 
7436 699   0 1795   0 1134   0 395   0 0 2 
7916 377 318 0.457554 1371 700 0.338001 847 512 0.3767476 278 431 0.6078984 0.445050245 1 
8058 445 227 0.3377976 1505 449 0.2297851 925 323 0.2588141 320 309 0.491256 0.329413185 1 
8089 145 391 0.7294776 333 792 0.704 217 556 0.7192755 108 533 0.8315133 0.746066606 1 
8144 234 160 0.4060914 781 346 0.3070098 563 248 0.3057953 180 215 0.5443038 0.390800061 1 
65 
Sample 16I 16A Ratio A/I 9I 9A Ratio A/I 8I 8A Ratio A/I 17I 17A Ratio A/I Average SNP ratio Zygosity* 
8147 166 159 0.4892308 542 297 0.3539928 376 229 0.3785124 128 196 0.6049383 0.456668572 1 
8159 332 228 0.4071429 1064 468 0.305483 687 334 0.3271303 233 310 0.5709024 0.402664636 1 
8305 221 198 0.4725537 773 451 0.3684641 533 320 0.3751465 177 271 0.6049107 0.455268752 1 
8434 352 186 0.3457249 1139 365 0.2426862 715 266 0.2711519 256 261 0.5048356 0.341099638 1 
8577 50 176 0.7787611 157 355 0.6933594 97 263 0.7305556 50 238 0.8263889 0.75726622 1 
8717 432 194 0.3099042 1173 299 0.203125 757 251 0.2490079 245 204 0.454343 0.304095019 1 
8741 1280 519 0.2884936 4408 963 0.1792962 2372 624 0.2082777 743 587 0.4413534 0.279355229 1 
8742 450 131 0.2254733 1465 261 0.1512167 1082 189 0.1487018 322 185 0.3648915 0.222570834 1 
8769 1451 610 0.2959728 3702 852 0.1870883 2359 682 0.2242683 838 638 0.4322493 0.28489469 1 
8811 367   0 825   0 545   0 189   0 0 2 
8821 1002 394 0.282235 2576 542 0.1738294 1629 446 0.2149398 568 404 0.4156379 0.271660488 1 
8829 744 273 0.2684366 2657 474 0.1513893 1442 319 0.1811471 427 307 0.4182561 0.254807279 1 
8859 533 268 0.3345818 1665 444 0.2105263 1105 360 0.2457338 305 286 0.4839255 0.318691857 1 
8916 253 180 0.4157044 783 367 0.3191304 524 278 0.3466334 184 231 0.5566265 0.409523686 1 
9032 543 376 0.4091404 1818 641 0.2606751 1194 528 0.3066202 306 406 0.5702247 0.386665092 1 
9134 643 428 0.3996265 1934 736 0.2756554 1263 598 0.3213326 389 462 0.5428907 0.38487632 1 
9207 462 333 0.4188679 1434 591 0.2918519 937 485 0.3410689 282 363 0.5627907 0.403644848 1 
9238 554 229 0.2924649 1524 341 0.1828418 1026 284 0.2167939 313 242 0.436036 0.282034158 1 
9292 403 149 0.2699275 1367 297 0.1784856 961 220 0.1862828 303 197 0.394 0.257173981 1 
9384 130 342 0.7245763 343 770 0.6918239 211 556 0.7249022 102 505 0.8319605 0.743315712 1 
9563 272 274 0.5018315 821 539 0.3963235 520 407 0.4390507 192 369 0.657754 0.498739936 1 
9660 1399 491 0.2597884 4807 863 0.1522046 2526 584 0.1877814 849 557 0.3961593 0.248983403 1 
9933 112 459 0.8038529 227 876 0.7941976 178 707 0.7988701 50 514 0.9113475 0.827067027 1 
9961   596 1   1040 1   675 1   649 1 1 0 























MEPY AVG CBD (3) STD CBD 
1.06 0.004 0.004 0.005 0.004333333 0.00057735 1.06 0.014 0.015 0.013 0.014 0.001 
3.125 0.01 0.009 0.01 0.009666667 0.00057735 3.125 0.033 0.035 0.031 0.033 0.002 
6.25 0.021 0.022 0.023 0.022 0.001 6.25 0.078 0.079 0.074 0.077 0.002645751 
12.5 0.049 0.049 0.055 0.051 0.003464102 12.5 0.182 0.186 0.176 0.181333333 0.005033223 
25 0.111 0.109 0.124 0.114666667 0.008144528 25 0.434 0.43 0.411 0.425 0.012288206 
50 0.256 0.241 0.283 0.26 0.021283797 50 1 0.965 0.932 0.965666667 0.034004902 
100 0.578 0.547 0.661 0.595333333 0.058943476 100 2.257 2.16 2.149 2.188666667 0.059433436 












STD CBN  Controls-Day 1 CBD THC CBN 
 1.06 0.037 0.036 0.032 0.035 0.002646  High (200) 185.0481928 239.6969697 192.3133 
3.125 0.082 0.08 0.076 0.079333 0.003055  Med (50) 43.96385542 45.03030303 44.11709 
6.25 0.191 0.177 0.177 0.181667 0.008083  Low (6.125) 7.979919679 8.666666667 8.89557 
12.5 0.446 0.412 0.411 0.423 0.019925  Controls-Day 2 CBD THC CBN 
25 1.04 0.948 0.935 0.974333 0.057239  High (200) 195.982906 239.6969697 192.3133 
50 2.395 2.131 2.203 2.243 0.13647  Med (50) 45.85470085 45.03030303 44.11709 
100 5.511 4.879 5.125 5.171667 0.318574  Low (6.125) 7.564102564 8.666666667 8.89557 
200 12.637 11.043 11.695 11.79167 0.801385  Controls-Day 3 CBD THC CBN 
       High (200) 205.3950617 205.4 207.6706 
       Med (50) 43.08230453 46.73333333 43.67747 


















diltion, etc %CBN 
254 0 4.77686 0.003981 0.398072 1.012 156.209 0.130174 13.01741 0.043 6.20339 0.005169 0.516949 
255 0.023 5.727273 0.004773 0.477273 0.91 140.9851 0.117488 11.74876 0.888 20.52542 0.017105 1.710452 
275 0.007 5.066116 0.004222 0.422176 0.16 29.04478 0.024204 2.420398 0.354 11.47458 0.009562 0.956215 
365 0 4.77686 0.003981 0.398072 0.559 88.59701 0.073831 7.383085 0.166 8.288136 0.006907 0.690678 
367 0 4.77686 0.003981 0.398072 0.108 21.28358 0.017736 1.773632 0.186 8.627119 0.007189 0.718927 
452 0.009 5.14876 0.004291 0.429063 1.191 182.9254 0.152438 15.24378 0.476 13.54237 0.011285 1.128531 
466 0.374 20.2314 0.01686 1.68595 0.118 22.77612 0.01898 1.89801 0.463 13.32203 0.011102 1.110169 
565 0 4.77686 0.003981 0.398072 0.28 46.95522 0.039129 3.912935 0.093 7.050847 0.005876 0.587571 
597 0 4.77686 0.003981 0.398072 0.299 49.79104 0.041493 4.149254 0.024 5.881356 0.004901 0.490113 
661 0 4.77686 0.003981 0.398072 0.19 33.52239 0.027935 2.793532 0.026 5.915254 0.004929 0.492938 
777 0.405 21.5124 0.017927 1.7927 0.138 25.76119 0.021468 2.146766 0.151 8.033898 0.006695 0.669492 
866 0 4.77686 0.003981 0.398072 0.649 102.0299 0.085025 8.502488 0.045 6.237288 0.005198 0.519774 
956 0.002 4.859504 0.00405 0.404959 0.162 29.34328 0.024453 2.445274 0.104 7.237288 0.006031 0.603107 
1072 0.006 5.024793 0.004187 0.418733 0.567 89.79104 0.074826 7.482587 0.203 8.915254 0.007429 0.742938 
1187 0.004 4.942149 0.004118 0.411846 0.108 21.28358 0.017736 1.773632 0.453 13.15254 0.01096 1.096045 
1220 0 4.77686 0.003981 0.398072 0.419 67.70149 0.056418 5.641791 0.028 5.949153 0.004958 0.495763 
1250 0.019 5.561983 0.004635 0.463499 0.246 41.8806 0.0349 3.49005 0.456 13.20339 0.011003 1.100282 
1365 0 4.77686 0.003981 0.398072 0.716 112.0299 0.093358 9.335821 0.062 6.525424 0.005438 0.543785 
1467 0 4.77686 0.003981 0.398072 0.365 59.64179 0.049701 4.970149 0.05 6.322034 0.005268 0.526836 
1688 0.004 4.942149 0.004118 0.411846 0.665 104.4179 0.087015 8.701493 0.382 11.94915 0.009958 0.995763 
1697 0.08 8.082645 0.006736 0.673554 0.186 32.92537 0.027438 2.743781 0.027 5.932203 0.004944 0.49435 
1778 0 4.77686 0.003981 0.398072 0.443 71.28358 0.059403 5.940299 0.194 8.762712 0.007302 0.730226 
1868 0.022 5.68595 0.004738 0.473829 0.218 37.70149 0.031418 3.141791 0.744 18.08475 0.015071 1.507062 




















diltion, etc %CBN 
2227 0 4.77686 0.003981 0.398072 0.394 63.97015 0.053308 5.330846 0.009 5.627119 0.004689 0.468927 
2251 0.133 10.27273 0.008561 0.856061 0.133 25.01493 0.020846 2.084577 0.838 19.67797 0.016398 1.639831 
2255 0.003 4.900826 0.004084 0.408402 0.511 81.43284 0.067861 6.78607 0.056 6.423729 0.005353 0.535311 
2517 0.017 5.479339 0.004566 0.456612 0.067 15.16418 0.012637 1.263682 0.288 10.35593 0.00863 0.862994 
2761 0.006 5.024793 0.004187 0.418733 0.737 115.1642 0.09597 9.597015 0.537 14.57627 0.012147 1.214689 
3056 1.485 66.1405 0.055117 5.511708 0.243 41.43284 0.034527 3.452736 0.146 7.949153 0.006624 0.662429 
3579 0.008 5.107438 0.004256 0.42562 0.3 49.9403 0.041617 4.161692 0.38 11.91525 0.009929 0.992938 
4344 0.017 5.479339 0.004566 0.456612 0.663 104.1194 0.086766 8.676617 0.164 8.254237 0.006879 0.687853 
4606 0.004 4.942149 0.004118 0.411846 0.27 45.46269 0.037886 3.788557 0.5 13.94915 0.011624 1.162429 
5075 0.005 4.983471 0.004153 0.415289 0.983 151.8806 0.126567 12.65672 0.158 8.152542 0.006794 0.679379 
5546 0.015 5.396694 0.004497 0.449725 0.126 23.97015 0.019975 1.997512 0.993 22.30508 0.018588 1.858757 
5725 0 4.77686 0.003981 0.398072 0.569 90.08955 0.075075 7.507463 0.113 7.389831 0.006158 0.615819 
5774 0.031 6.057851 0.005048 0.504821 0.037 10.68657 0.008905 0.890547 1.048 23.23729 0.019364 1.936441 
5888 0.005 4.983471 0.004153 0.415289 0.666 104.5672 0.087139 8.71393 0.125 7.59322 0.006328 0.632768 
5931 0.002 4.859504 0.00405 0.404959 0.196 34.41791 0.028682 2.868159 0.471 13.45763 0.011215 1.121469 
6043 0.009 5.14876 0.004291 0.429063 0.631 99.34328 0.082786 8.278607 0.105 7.254237 0.006045 0.60452 
6264 0.003 4.900826 0.004084 0.408402 0.519 82.62687 0.068856 6.885572 0.074 6.728814 0.005607 0.560734 
6352 0 4.77686 0.003981 0.398072 0.339 55.76119 0.046468 4.646766 0.231 9.389831 0.007825 0.782486 
6361 0 4.77686 0.003981 0.398072 0.69 108.1493 0.090124 9.012438 0.147 7.966102 0.006638 0.663842 
6922 0 4.77686 0.003981 0.398072 0.502 80.08955 0.066741 6.674129 0.082 6.864407 0.00572 0.572034 
7326 0.007 5.066116 0.004222 0.422176 0.624 98.29851 0.081915 8.191542 0.893 20.61017 0.017175 1.717514 
7436 0.003 4.900826 0.004084 0.408402 0.639 100.5373 0.083781 8.378109 0.132 7.711864 0.006427 0.642655 
7916 0.006 5.024793 0.004187 0.418733 0.502 80.08955 0.066741 6.674129 0.084 6.898305 0.005749 0.574859 




















diltion, etc %CBN 
8144 0.004 4.942149 0.004118 0.411846 0.409 66.20896 0.055174 5.517413 0.332 11.10169 0.009251 0.925141 
8159 0 4.77686 0.003981 0.398072 0.751 117.2537 0.097711 9.771144 0.534 14.52542 0.012105 1.210452 
8305 0 4.77686 0.003981 0.398072 0.711 111.2836 0.092736 9.273632 0.614 15.88136 0.013234 1.323446 
8434 0.012 5.272727 0.004394 0.439394 0.503 80.23881 0.066866 6.686567 0.633 16.20339 0.013503 1.350282 
8577 0 4.77686 0.003981 0.398072 1.452 221.8806 0.1849 18.49005 0.165 8.271186 0.006893 0.689266 
8717 0 4.77686 0.003981 0.398072 0.163 29.49254 0.024577 2.457711 0.06 6.491525 0.00541 0.54096 
8741 0 4.77686 0.003981 0.398072 0.754 117.7015 0.098085 9.808458 0.036 6.084746 0.005071 0.507062 
8742 0 4.77686 0.003981 0.398072 0.628 98.89552 0.082413 8.241294 0.446 13.0339 0.010862 1.086158 
8769 0 4.77686 0.003981 0.398072 0.621 97.85075 0.081542 8.154229 0.033 6.033898 0.005028 0.502825 
8811 0 4.77686 0.003981 0.398072 0.744 116.209 0.096841 9.68408 0.052 6.355932 0.005297 0.529661 
8821 0.483 24.73554 0.020613 2.061295 0.169 30.38806 0.025323 2.532338 0.008 5.610169 0.004675 0.467514 
8829 0 4.77686 0.003981 0.398072 0.761 118.7463 0.098955 9.895522 0.041 6.169492 0.005141 0.514124 
8859 0 4.77686 0.003981 0.398072 0.266 44.86567 0.037388 3.738806 0.019 5.79661 0.004831 0.483051 
8916 0 4.77686 0.003981 0.398072 0.232 39.79104 0.033159 3.31592 0.61 15.81356 0.013178 1.317797 
9032 0 4.77686 0.003981 0.398072 0.588 92.92537 0.077438 7.743781 0.019 5.79661 0.004831 0.483051 
9134 0 4.77686 0.003981 0.398072 0.696 109.0448 0.090871 9.087065 0.041 6.169492 0.005141 0.514124 
9207 0 4.77686 0.003981 0.398072 1.043 160.8358 0.13403 13.40299 0.051 6.338983 0.005282 0.528249 
9238 0 4.77686 0.003981 0.398072 0.419 67.70149 0.056418 5.641791 0.038 6.118644 0.005099 0.509887 
9292 0 4.77686 0.003981 0.398072 0.541 85.91045 0.071592 7.159204 0.809 19.18644 0.015989 1.59887 
9384 0.005 4.983471 0.004153 0.415289 0.251 42.62687 0.035522 3.552239 0.513 14.16949 0.011808 1.180791 
9563 0 4.77686 0.003981 0.398072 0.306 50.83582 0.042363 4.236318 0.47 13.44068 0.011201 1.120056 
9660 0 4.77686 0.003981 0.398072 0.329 54.26866 0.045224 4.522388 0.022 5.847458 0.004873 0.487288 
9933 0 4.77686 0.003981 0.398072 0.897 139.0448 0.115871 11.58706 0.014 5.711864 0.00476 0.475989 















Dependent Variable: PCT THC 
Class Level Information 
Class Levels Values 
SNP 3 0, 1, 2 
Type 3 Test of Fixed Effects 
Effect Numerator DF Denominator DF F Value Pr>F 
SNP 2 72 0.57 0.5687 
Simple Statistics 
Variable N Mean Std Sev. Sum Minimum Maximum 
PCT THC 75 6.54892 3.79387 491.16915 0.89055 18.49005 
PCT 16 75 0.40708 0.21612 30.53107 0 1.00000 
PCT 9 75 0.31301 0.22928 23.47596 0 1.00000 
PCT 8 75 0.34172 0.22847 25.62883 0 1.00000 
PCT 17 75 0.53234 0.21083 39.92566 0 1.00000 
PCT All 75 0.39854 0.21878 29.89038 0 1.00000 
PCT 16_9_8 75 0.35394 0.22394 26.54529 0 1.00000 
PCT 16_9_17 75 0.41748 0.21606 31.31090 0 1.00000 
PCT 16_8_17 75 0.42705 0.21636 32.02852 0 1.00000 
PCT 9_8_17 75 0.39569 0.21979 29.67681 0 1.00000 
PCT 6_9 75 0.36005 0.22179 27.00352 0 1.00000 
PCT 16_8 75 0.37440 0.22178 28.07995 0 1.00000 
PCT 16_17 75 0.46971 0.21223 35.22837 0 1.00000 
PCT 9_8 75 0.32737 0.22875 24.55239 0 1.00000 
PCT 9_17 75 0.42268 0.21617 31.70081 0 1.00000 
PCT 8_17 75 0.43703 0.21665 32.77724 0 1.00000 
Least Squares Means 
Effect SNP Estimate Standard Error 
SNP 0 6.7405 2.2033 
SNP 1 6.4250 0.4628 
SNP 2 8.5118 1.9081 
Pearson Correlation Coefficients, N = 75 
Prob > |r| under H0: Rho=0 
Variable PCT THC R2 
PctTHC 1.00000  
Pct16 0.04368 0.7098 
Pct9 0.04673 0.6906 
Pct8 0.03796 0.7464 
Pct17 0.00241 0.9836 
PctAll 0.03352 0.7753 
Pct16_9_8 0.04291 0.7147 
Pct16_9_17 0.03188 0.7860 
Pct16_8_17 0.02869 0.8070 
Pct9_8_17 0.03017 0.7972 
Pct16_9 0.04544 0.6987 
Pct16_8 0.04084 0.7280 
Pct16_17 0.02344 0.8418 
Pct9_8 0.04237 0.7181 
Pct9_17 0.02596 0.8251 
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